var title_f7_22_7520="Tx post vaginal wall def 9";
var content_f7_22_7520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of a left lateral posterior vaginal wall support defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7520=[""].join("\n");
var outline_f7_22_7520=null;
var title_f7_22_7521="Saphenous nerve block";
var content_f7_22_7521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Saphenous nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medial view of the extremity: For saphenous nerve block,&nbsp;the tibial tuberosity is first marked. A subcutaneous ring of local anesthestic is administered posterior to the medial tibial condyle, or alternatively, around the saphenous vein if it is easily visualized with ultrasound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7521=[""].join("\n");
var outline_f7_22_7521=null;
var title_f7_22_7522="M mode cardiomyopathy I";
var content_f7_22_7522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echoardiogram in cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode echocardiogram (left panel) and the left ventriculogram (right panel) are from a patient with a cardiomyopathy. The ventriculogram shows global hypokinesis, large end-diastolic (EDV) and end-systolic volumes (ESV), and an ejection fraction (EF) of 32 percent. The M-mode echocardiogram shows reduced septal (Sept) motion, a large left (LV) and right ventricle (RV) and an EPSS of 20 mm.",
"    <div class=\"footnotes\">",
"     Dia: diastole; Sys: systole.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7522=[""].join("\n");
var outline_f7_22_7522=null;
var title_f7_22_7523="Histoplasma blood smear";
var content_f7_22_7523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Histoplasma capsulatum on blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histoplasma capsulatum seen inside a white blood cell on a peripheral blood smear from a patient with disseminated histoplasmosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7523=[""].join("\n");
var outline_f7_22_7523=null;
var title_f7_22_7524="Tech factors add imaging";
var content_f7_22_7524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Technical factors leading to additional imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On a standard CC view performed during routine screening mammogram, the nipple (arrows) can appear as a nodule (Panel A) if not properly positioned leading to additional work up. When the CC view of the same breast is repeated with the nipple in profile (Panel B), it becomes clear that there is no lesion. Similarly, deodorant may appear as very faint radiodensities. This is usually seen in the axillary portion of the breast on the MLO view, mimicking microcalcifications (Panel C). A repeat MLO view (Panel D) after washing the axilla shows normal appearance.",
"    <div class=\"footnotes\">",
"     CC: craniocaudal; MLO: mediolateral oblique.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7524=[""].join("\n");
var outline_f7_22_7524=null;
var title_f7_22_7525="Floctafenine: Patient drug information";
var content_f7_22_7525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Floctafenine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14359?source=see_link\">",
"     see \"Floctafenine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F242482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Floctafenine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12934739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to floctafenine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697684",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not helpful during a migraine attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, GI (gastrointestinal) disease, heart disease, liver disease, very bad kidney disease, ulcer or bleeding from stomach or bowel, or weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12439 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7525=[""].join("\n");
var outline_f7_22_7525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242482\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12934739\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029729\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029728\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029733\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029734\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029736\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029731\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029732\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029737\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029738\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14359?source=related_link\">",
"      Floctafenine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_22_7526="Cabozantinib: Drug information";
var content_f7_22_7526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cabozantinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/29/10710?source=see_link\">",
"    see \"Cabozantinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15674859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16047819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cometriq&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15674860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15846538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Medullary thyroid cancer, metastatic:",
"     </b>",
"     Oral: 140 mg once daily until disease progression or unacceptable toxicity occurs; do not exceed 180 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     Do not take a missed dose within 12 hours of the next dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Strong CYP3A4 inhibitors:",
"     </i>",
"     Avoid concomitant use; if concomitant use is required,",
"     <b>",
"      reduce",
"     </b>",
"     the daily dose of cabozantinib by 40 mg (ie, from 140 mg to 100 mg daily or from 100 mg to 60 mg daily). If the strong inhibitor is discontinued, allow ~2-3 days to elapse prior to adjusting the cabozantinib dose upwards to the dose used prior to the initiation of the strong inhibitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Strong CYP3A4 inducers:",
"     </i>",
"     Avoid concomitant use; if concomitant use is required,",
"     <b>",
"      increase",
"     </b>",
"     the daily dose by 40 mg (ie, from 140 mg to 180 mg daily or from 100 mg to 140 mg daily). If the strong inducer is discontinued, allow ~2-3 days to elapse prior to reducing the cabozantinib dose to the dose used prior to the initiation of the strong inducer.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15846558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15846559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (limited data available in patients with total bilirubin &gt;1.5 times ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate or severe impairment: Use is not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15846539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hematologic:",
"     </b>",
"     Withhold therapy for grade 4 hematologic adverse reactions. Upon return to baseline or improvement to grade 1, reduce the dose to 100 mg daily. If previously receiving 100 mg daily, resume therapy at 60 mg daily. If previously receiving 60 mg daily, resume at 60 mg daily if tolerated; otherwise, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Other toxicity:",
"     </b>",
"     Grade 3 or higher nonhematologic toxicity or intolerable grade 2 toxicity: Upon return to baseline or improvement to grade 1, reduce the dose to 100 mg daily. If previously receiving 100 mg daily, resume therapy at 60 mg daily. If previously receiving 60 mg daily, resume at 60 mg daily if tolerated; otherwise, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Permanently discontinue for:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Malignant hypertension, hypertensive crisis, persistent uncontrolled hypertension despite optimal therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nephrotic syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reversible posterior leukoencephalopathy syndrome (RPLS)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Serious arterial thromboembolic event (eg, MI or cerebral infarction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Visceral perforation or fistula formation",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16047820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [each package contains four blister cards; each card contains the following]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cometriq&trade;: 60 mg daily-dose: 20 mg (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cometriq&trade;: 100 mg daily-dose: 80 mg (7s) and 20 mg (7s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cometriq&trade;: 140 mg daily-dose: 80 mg (7s) and 20 mg (21s)",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F16058319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Distribution of Cometriq&trade; is limited to Diplomat Specialty Pharmacy (855-253-3273).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15846579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally on an empty stomach (1 hour before or 2 hours after eating). Swallow whole; do not open capsules.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15674862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of progressive, metastatic medullary thyroid cancer (MTC)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15838145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cabozantinib may be confused with axitinib, bosutinib, cabazitaxel, crizotinib, dasatinib, imatinib, nilotinib, regorafenib, ruxolitinib, vandetanib, vemurafenib",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15809143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (33%; grades 3/4: 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (41%), dysphonia (20%), headache (18%), dizziness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Palmar-plantar erythrodysesthesia (50%; grades 3/4: 13%), hair color changes (34%), dry skin (19%), rash (19%), alopecia (16%), erythema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (52%), hypophosphatemia (28%), hypomagnesemia (19%), hypokalemia (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (63%), stomatitis (51%), weight loss (48%), appetite decreased (46%), nausea (43%), oral pain (36%), abnormal taste (34%), abdominal pain (27%), constipation (27%), vomiting (24%), dysphagia (13%), dyspepsia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphopenia (53%; grades 3/4: 16%), neutropenia (35%; grades 3/4: 3%), thrombocytopenia (35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (86%), AST increased (86%), alkaline phosphatase increased (52%), hyperbilirubinemia (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (21%), arthralgia (14%), muscle spasms (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Venous thromboembolism (6%), arterial thromboembolism (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Anxiety (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperkeratosis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyponatremia (10%), dehydration (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Hemorrhoids (9%), gastrointestinal perforation (3%), gastrointestinal fistula (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hemorrhage (&ge;grade 3: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal chest pain (9%), paresthesia (7%), peripheral neuropathy (5%), osteonecrosis of the jaw (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Nongastrointestinal fistula (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Reversible posterior leukoencephalopathy syndrome (RPLS), wound healing impaired",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15840645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15840658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic toxicity: Palmar-plantar erythrodysesthesia syndrome (PPES) was commonly observed in clinical trials; severe PPES (&ge;grade 3) also occurred frequently. May require dosage reduction and/or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hemorrhage:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and occasionally fatal hemorrhage (including hemoptysis and gastrointestinal) has occurred with therapy. Monitor for signs/symptoms of bleeding and do not administer to patients with severe hemorrhage",
"     </b>",
"     or a recent history of hemorrhage or hemoptysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypertension: Stage 1 or 2 hypertension was observed in more than half of cabozantinib-treated patients and occurred more frequently than in placebo-treated patients. Monitor blood pressure prior to therapy initiation and frequently thereafter; withhold for hypertension that is uncontrolled with appropriate medical management. May require cabozantinib dosage reduction and/or therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw occurred rarely; oral examinations should be performed prior to and periodically throughout therapy. Patients should maintain proper oral hygiene practices; if possible, withhold therapy for at least 28 days prior to scheduled invasive dental procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Perforations and fistulas:",
"     <b>",
"      [U.S. Boxed Warning]: Serious  gastrointestinal (GI) perforations and fistulas have been reported; discontinue for GI perforation or fistulation formation.",
"     </b>",
"     GI fistula may be fatal. Tracheal/esophageal fistulas were also noted; some cases were fatal. Monitor for signs/symptoms of perforations and fistulas; if observed, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Proteinuria: Proteinuria occurred in a small number of patients receiving cabozantinib as compared to placebo; nephrotic syndrome was also reported (rare). Monitor urine protein regularly and discontinue therapy if nephrotic syndrome develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS), also referred to as posterior reversible leukoencephalopathy syndrome (PRES), occurred rarely in clinical studies. Monitor for signs/symptoms of RPLS (seizures, headache, visual disturbances, confusion or altered mental function); if diagnosis confirmed, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolic events: An increased incidence of thrombotic events was seen in cabozantinib-treated patients versus placebo; discontinue therapy in patients who develop an acute myocardial infarction or other clinically significant arterial thromboembolic event.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Wound healing impairment: Cabozantinib inhibits vascular endothelial growth factor receptors 1, 2, and 3; wound complications have been reported with therapy. Hold treatment at least 28 days prior to scheduled surgery; resume based on judgment of adequate wound healing post surgery. Withhold treatment in patients with dehiscence or other wound healing complications requiring intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Safety and efficacy of cabozantinib have not been established in patients with serum bilirubin &ge;1.5 times ULN. Use is not recommended in moderate or severe hepatic impairment; pharmacokinetics have not been studied and there are limited data in patients with serum bilirubin &gt;1.5 times ULN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Avoid the use of concomitant strong CYP3A4 inducers and/or strong CYP3A4 inhibitors. Dosage adjustments are required if concurrent therapy is unavoidable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16061023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16061021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15846439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     A high-fat meal increased C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC by 41% and 57%, respectively compared to the fasted state. Management: Must be taken on an empty stomach, at least 1 hour before and 2 hours after food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cabozantinib serum concentrations may be increased when taken with grapefruit or grapefruit juice; Management: avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid St John&rsquo;s wort (may decrease cabozantinib exposure).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15840641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15840642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on its mechanism of action, adverse effects on pregnancy would be expected. In animal reproduction studies, teratogenic effects (fetal loss, malformations, and skeletal/visceral variations) were observed with doses below the recommended human dose. Patients (male and female) should use effective contraception during therapy and for up to 4 months after therapy completion.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15840643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15840644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if cabozantinib is excreted into breast milk. According to the manufacturer, the decision to discontinue cabozantinib or to discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15846578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be taken on an empty stomach, at least 1 hour before or 2 hours after food; avoid grapefruit and grapefruit juice throughout therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Cometriq (100 mg Daily Dose) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 X 80 &amp; 1 X 20 mg (14): $2970.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Cometriq (140 mg Daily Dose) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 X 80 &amp; 3 X 20 mg (28): $2970.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Cometriq (60 mg Daily Dose) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (21): $2970.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15846581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, liver function, CBC with differential and platelets, serum electrolytes; blood pressure (prior to initiation and regularly during therapy); monitor for perforations, fistulas, signs/symptoms of bleeding, palmar-plantar erythrodysesthesia syndrome (PPES), reversible posterior leukoencephalopathy syndrome (RPLS), proteinuria (regularly during therapy), osteonecrosis of the jaw (perform oral examination prior to initiation and periodically during therapy), wound healing complications, diarrhea, stomatitis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15846442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cabozantinib is a potent inhibitor of proinvasive receptor tyrosine kinases (RTKs), including AXL, FLT-3, KIT, MET, RET, TIE-2, TRKB, and VEGFR-1, -2, and -3; induces apoptosis of cancer cells and suppresses tumor growth, metastasis, and angiogenesis (Yakes, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15846444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~349 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &ge;99.7% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (54%); urine (27%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Durante C, Russo D, Verrienti A, et al, &ldquo;XL184 (Cabozantinib) for Medullary Thyroid Carcinoma,&rdquo;",
"      <i>",
"       Expert Opin Investig Drugs",
"      </i>",
"      , 2011, 20(3):407-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/22/7526/abstract-text/21314233/pubmed\" id=\"21314233\" target=\"_blank\">",
"        21314233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurzrock R, Sherman SI, Ball DW, et al, &ldquo;Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(19):2660-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/22/7526/abstract-text/21606412/pubmed\" id=\"21606412\" target=\"_blank\">",
"        21606412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith DC, Smith MR, Sweeney C, et al, &ldquo;Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2013, 31(4):412-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/22/7526/abstract-text/23169517/pubmed\" id=\"23169517\" target=\"_blank\">",
"        23169517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yakes FM, Chen J, Tan J, et al, &ldquo;Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth,&rdquo;",
"      <i>",
"       Mol Cancer Ther",
"      </i>",
"      , 2011, 10(12):2298-308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/22/7526/abstract-text/21926191/pubmed\" id=\"21926191\" target=\"_blank\">",
"        21926191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87299 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7526=[""].join("\n");
var outline_f7_22_7526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15674859\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16047819\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15674860\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846538\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846558\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846559\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846539\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16047820\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058319\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846579\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15674862\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838145\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15809143\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840658\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061023\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061021\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846439\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840641\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840642\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840643\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840644\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846578\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570462\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846581\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846442\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846444\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87299|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/29/10710?source=related_link\">",
"      Cabozantinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_22_7527="Hiatus hernia";
var content_f7_22_7527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hiatus hernia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7527/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7527/contributors\">",
"     Peter J Kahrilas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7527/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7527/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7527/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/22/7527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hiatus hernia is a frequent finding by both radiologists and gastroenterologists. However, estimates of the prevalence of hiatus hernia vary widely due to inconsistencies in definition, widespread confusion regarding the clinical implications of a hiatal hernia, and the normal function of the gastroesophageal junction. This topic review will discuss both the reasons for the confusion and the significance of hiatus hernia. The general principles for the diagnosis and surgical management of paraesophageal hernia and medical management of gastroesophageal reflux disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19128?source=see_link\">",
"     \"Paraesophageal hernia: Clinical features and surgical repair\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY OF THE GASTROESOPHAGEAL JUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal end of the esophagus is anchored to the diaphragm by the phrenoesophageal membrane, formed by the fused endothoracic and endoabdominal fascia. This elastic membrane inserts circumferentially into the esophageal musculature, very close to the squamocolumnar junction which resides within the diaphragmatic hiatus.",
"   </p>",
"   <p>",
"    This configuration is altered during swallow-initiated peristalsis, a sequenced contraction of both the longitudinal and circular muscle responsible for bolus propulsion through the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/1\">",
"     1",
"    </a>",
"    ]. With contraction of the esophageal longitudinal muscle, the esophagus shortens and the phrenoesophageal membrane is stretched; its elastic recoil is then responsible for pulling the squamocolumnar junction back to its normal position following each swallow. This is, in effect, \"physiologic herniation,\" since the gastric cardia tents through the diaphragmatic hiatus with each swallow (",
"    <a class=\"graphic graphic_figure graphicRef61193 \" href=\"UTD.htm?41/18/42275\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/2\">",
"     2",
"    </a>",
"    ]. This paradox has led to a confusing array of terminology (",
"    <a class=\"graphic graphic_figure graphicRef72582 \" href=\"UTD.htm?36/2/36896\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The globular structure seen radiographically that forms above the diaphragm and beneath the tubular esophagus during deglutition is termed the phrenic ampulla; it is bounded from above by the distal esophagus and from below by the crural diaphragm (",
"    <a class=\"graphic graphic_figure graphicRef72582 \" href=\"UTD.htm?36/2/36896\">",
"     figure 2",
"    </a>",
"    ). Emptying of the ampulla occurs between inspirations in conjunction with relengthening of the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The repetitive stress of swallowing as well as that associated with abdominal straining and episodes of vomiting subject the phrenoesophageal membrane to substantial wear and tear, making it a plausible target of age-related degeneration. Another potential source of stress on the phrenoesophageal membrane is tonic contraction of the esophageal longitudinal muscle induced by gastroesophageal reflux and mucosal acidification [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aside from its antegrade propulsive function, the gastroesophageal junction also serves to minimize gastroesophageal reflux. This is accomplished by a complex valvular mechanism, the function of which is partly attributable to the esophagus, partly to the stomach, and partly to the crural diaphragm. The esophageal element has been extensively analyzed and consists of the lower esophageal sphincter (LES), a 2 cm segment of tonically contracted smooth muscle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proximal margin of the LES extends up to and a short distance proximal to the squamocolumnar junction.",
"     </li>",
"     <li>",
"      The distal margin of the LES is more difficult to define but careful anatomic studies suggest that it is composed of elements of the gastric musculature, the opposing clasp, and sling fibers of the gastric cardia (",
"      <a class=\"graphic graphic_figure graphicRef69389 \" href=\"UTD.htm?34/16/35087\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surrounding the LES at the level of the squamocolumnar junction is the crural diaphragm, composed mainly of the right diaphragmatic crus [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elegant physiologic studies have demonstrated that diaphragmatic contraction augments gastroesophageal junction pressure, in essence serving as an external sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/8\">",
"     8",
"    </a>",
"    ]. Furthermore, if the esophagogastric junction is defined as either the end of the LES or the point at which the tubular esophagus joins the saccular stomach, there are normally about 2 cm of tubular esophagus within the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF HIATAL HERNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general terms, hiatus hernia refers to herniation of elements of the abdominal cavity through the esophageal hiatus of the diaphragm. The most comprehensive classification scheme recognizes four types of hiatal hernia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type I: Sliding hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I or sliding hiatal hernia accounts for more than 95 percent of cases. This type of hernia is characterized by widening of the muscular hiatal tunnel and circumferential laxity of the phrenoesophageal membrane, allowing a portion of the gastric cardia to herniate upward. The phrenoesophageal membrane remains intact and the hernia is contained within the posterior mediastinum (",
"    <a class=\"graphic graphic_figure graphicRef62190 \" href=\"UTD.htm?30/59/31671\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In marginal instances, type I hiatal hernia is simply an exaggeration of the normal phrenic ampulla, making its identification dependent on measurement technique. However, when a sliding hiatal hernia enlarges further so that more than 3 cm of gastric pouch is herniated upward, its presence is obvious regardless of measurement technique because gastric folds are evident traversing the diaphragm both during swallow-induced shortening and at rest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72064 \" href=\"UTD.htm?41/1/42004\">",
"     image 1",
"    </a>",
"    ). The progression from normal anatomy to obvious type I hernia is well illustrated in an analysis of the endoscopic appearance of the cardia, as viewed from beneath with the endoscope directed toward the hiatus (",
"    <a class=\"graphic graphic_figure graphicRef54169 \" href=\"UTD.htm?36/36/37447\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hiatal hernias that are larger than 2 cm in axial span can be diagnosed easily by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow radiography, endoscopy, or esophageal manometry. By contrast, endoscopy and radiography are much less accurate for defining smaller hernias. Because the esophagogastric junction is highly mobile, reliable detection of small hiatal hernias (defined as axial separation between the lower esophageal sphincter [LES] and crural diaphragm) can only be accomplished with high-resolution manometry, a technique that permits real-time localization of the esophagogastric junction components without swallow or distention related artifact [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of most sliding hiatal hernias is speculative, but there are instances in which trauma, congenital malformation, and iatrogenic factors can be clearly implicated. The incidence of type I hiatal hernia is also unclear. Estimates of prevalence vary enormously, from 10 to 80 percent of the adult population in North America, largely because of the inherent subjectivity in defining this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all probability, most small hiatal hernias are asymptomatic and, even with larger type I hernias, the main clinical implication is the propensity to develop gastroesophageal reflux disease (GERD). The likelihood of symptomatic gastroesophageal reflux increases with the size of the hiatal hernia. It is rare for complications other than reflux to occur as a result of a type I hiatal hernia; furthermore, even these complications are usually related to reflux. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Symptoms'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"     \"Complications of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type II, III, and IV: Paraesophageal hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The less common types of hiatal hernia, types II, III, and IV, are varieties of \"paraesophageal\" hernias which account for about 5 percent of all hiatal hernias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. Although their etiology is usually unclear, paraesophageal hernias are a recognized complication of surgical dissection of the hiatus as occurs during antireflux procedures, esophagomyotomy, or partial gastrectomy.",
"   </p>",
"   <p>",
"    A type II hernia results from a localized defect in the phrenoesophageal membrane, while the gastroesophageal junction remains fixed to the preaortic fascia and the median arcuate ligament. Thus, the gastric fundus serves as the leading point of herniation (",
"    <a class=\"graphic graphic_figure graphicRef62190 \" href=\"UTD.htm?30/59/31671\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Either as cause or effect, paraesophageal hernias are associated with abnormal laxity of structures normally preventing displacement of the stomach &mdash; the gastrosplenic and gastrocolic ligaments. As the hernia enlarges, the greater curvature of the stomach rolls up into the thorax. Because the stomach is fixed at the gastroesophageal junction, the herniated stomach tends to rotate around its longitudinal axis, resulting in an organoaxial volvulus (",
"    <a class=\"graphic graphic_figure graphicRef73205 \" href=\"UTD.htm?26/59/27572\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/13\">",
"     13",
"    </a>",
"    ]. Infrequently, rotation occurs around the transverse axis resulting in a mesenteroaxial volvulus (",
"    <a class=\"graphic graphic_figure graphicRef73205 \" href=\"UTD.htm?26/59/27572\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/13\">",
"     13",
"    </a>",
"    ]. Paraesophageal hernias are best diagnosed with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, although their presence is usually suggested by endoscopy. In instances of paraesophageal hernia involving organs other than just the stomach, a definitive diagnosis is established with computed tomography (CT) or magnetic resonance imaging (MRI).",
"   </p>",
"   <p>",
"    The natural history of a type II hernia is progressive enlargement. As a result, the entire stomach eventually herniates, with the pylorus juxtaposed to the gastric cardia, forming an upside-down, intrathoracic stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Types III and IV hiatal hernias are variants of the type II (purely paraesophageal) hernia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type III hernias have elements of both types I and II. With progressive enlargement of the hernia through the hiatus, the phrenoesophageal membrane stretches, displacing the gastroesophageal junction above the diaphragm, thereby adding a sliding element to the type II hernia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50536 \" href=\"UTD.htm?15/36/15939\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type IV hiatus hernia is associated with a large defect in the phrenoesophageal membrane, allowing other organs, such as the colon, spleen, pancreas, and small intestine, to enter the hernia sac.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hiatal hernia is not a diagnosis that is pursued in and of itself. It is usually discovered as a finding on upper gastrointestinal studies or endoscopy. Many patients with a type II hernia are either asymptomatic or have only vague, intermittent symptoms. The most common symptoms are epigastric or substernal pain, postprandial fullness, substernal fullness, nausea, and retching. An upright radiograph of the thorax may be diagnostic, revealing a retrocardiac air-fluid level within a paraesophageal hernia or intrathoracic stomach.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    contrast studies are almost always diagnostic.",
"   </p>",
"   <p>",
"    Most complications of a type II hernia are reflective of the mechanical problem caused by the hernia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric volvulus can cause dysphagia, while postcibal pain is usually related to gastric torsion.",
"     </li>",
"     <li>",
"      Bleeding, although infrequent, occurs from gastric ulceration, gastritis, or erosions (Cameron lesions) within the incarcerated hernia pouch [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"       \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory complications result from mechanical compression of the lung by a large hernia or other organs herniating through the hiatus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Association of type I hiatus hernia with gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic and radiographic studies suggest that 50 to 94 percent of patients with gastroesophageal reflux disease (GERD) have a type I hiatal hernia compared to 13 to 59 percent of normals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. However, the importance of a type I hiatal hernia is obscured by the misconception that this is an all or none phenomenon. It is more useful to view type I hiatal hernia as a continuum of progressive disruption of the gastroesophageal junction (",
"    <a class=\"graphic graphic_figure graphicRef54169 \" href=\"UTD.htm?36/36/37447\">",
"     figure 5",
"    </a>",
"    ). Type I hiatus hernia impacts on reflux both by affecting the competence of the gastroesophageal junction in preventing reflux and in compromising the process of esophageal acid clearance once reflux has occurred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hiatus hernia and the diaphragmatic sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively recent physiologic investigations have advanced the \"two sphincter\" hypothesis of gastroesophageal junction competence, suggesting that both the lower esophageal sphincter (LES) and the crural diaphragm encircling the LES serve a sphincteric function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/8,15-18\">",
"     8,15-18",
"    </a>",
"    ]. In particular, the diaphragm augments the LES by a \"pinchcock\" effect during transient periods of increased intraabdominal pressure as occur during inspiration, coughing, or abdominal straining. Experiments that quantified and statistically modeled the susceptibility to reflux during abdominal straining concluded that susceptibility to this mode of reflux is proportional to the size of a type I hernia (",
"    <a class=\"graphic graphic_figure graphicRef60262 \" href=\"UTD.htm?3/15/3314\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, although neither hiatus hernia nor a hypotensive LES alone results in severe gastroesophageal junction incompetence, the two conditions interact with each other. This conclusion is consistent with the clinical experience that exercise, tight fitting garments, and activities involving bending at the waist exacerbate heartburn, especially after having consumed meals that reduce LES pressure. Both animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/20\">",
"     20",
"    </a>",
"    ] and detailed manometric studies in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/21\">",
"     21",
"    </a>",
"    ] also suggest that type I hiatus hernia in and of itself may diminish LES pressure. Furthermore, the compliance or distensibility of the esophagogastric junction during sphincter relaxation may be important in regulating both the volume and the",
"    <span class=\"nowrap\">",
"     air/liquid",
"    </span>",
"    content of gastric reflux. Compliance within the hiatus increases progressively when comparing normal controls to GERD patients without a hiatus hernia to GERD patients with an overt hiatus hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three other factors also appear to be important in patients with reflux associated with a hiatus hernia. A hiatus hernia is associated with a reduced threshold for eliciting tLESRs in response to gastric distension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/23\">",
"     23",
"    </a>",
"    ]. It is also associated with malfunction of the gastroesophageal barrier during periods of low LES pressure, during normal swallow-associated LES relaxation, and during deep inspiration or straining [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Compromise of esophageal emptying related to hiatus hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defining abnormality with esophagitis is excessive mucosal acid exposure which, in turn, is dependent upon both the frequency of reflux events and the time required to achieve acid clearance for each event. Prolongation of acid clearance among patients with reflux disease has long been recognized, especially with type I hiatus hernia while recumbent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/25\">",
"     25",
"    </a>",
"    ]. Hiatus hernias compromise fluid emptying from the distal esophagus by \"rereflux\" from the hernia sac during swallowing (",
"    <a class=\"graphic graphic_figure graphicRef72024 \" href=\"UTD.htm?15/56/16256\">",
"     figure 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rereflux occurs predominantly during inspiration and can be attributed to loss of the normal one-way valve function of the crural diaphragm. By pinching off the distal esophagus, the crural diaphragm prevents backward flow from the stomach during each inspiration when it would be favored by a positive abdominal-thoracic pressure gradient. This one-way valve function of the crural diaphragm is grossly impaired with large type I hernias because a gastric pouch persists above the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of an isolated, asymptomatic type I hiatal hernia is rarely indicated. If symptoms of gastroesophageal reflux disease (GERD) occur in association with a large hiatus hernia, either medical or surgical treatment is indicated to control the reflux. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the enlarging types II, III, and IV hernias pose a constant risk of serious complications. These hernias never regress and progressively enlarge. If left untreated, the paraesophageal hernia eventually reaches the stage of the giant intrathoracic stomach, at which point the prognosis is poor and the complication rate is high [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal management of patients with paraesophageal hernias has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/28\">",
"     28",
"    </a>",
"    ]. Some advocate surgical treatment even in the absence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/29\">",
"     29",
"    </a>",
"    ]. However, others advocate against prophylactic paraesophageal hernia repair for asymptomatic patients, as the mortality rate from elective paraesophageal hernia repair is reportedly 1.4 percent, while the probability of developing acute symptoms requiring emergent surgery is reportedly 1.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/30\">",
"     30",
"    </a>",
"    ]. The lifetime risk of developing acute symptoms requiring emergency surgery decreases exponentially with age after 65 years.",
"   </p>",
"   <p>",
"    When compared with open surgical repair of giant paraesophageal hernia, laparoscopic repair provided symptom improvement and a comparable low reoperation rate (3 percent) in a retrospective review of 662 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19128?source=see_link\">",
"     \"Paraesophageal hernia: Clinical features and surgical repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical approaches to type II hiatal hernias can be divided into five components, not all of which are required in each case [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduction of the herniated stomach into the abdomen",
"     </li>",
"     <li>",
"      Herniotomy (excision of the hernia sac)",
"     </li>",
"     <li>",
"      Herniorrhaphy (closure of the hiatal defect)",
"     </li>",
"     <li>",
"      An antireflux procedure",
"     </li>",
"     <li>",
"      Gastropexy (attachment of the stomach subdiaphragmatically to prevent reherniation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Opinion varies as to whether or not an antireflux procedure is necessary if concomitant pathologic reflux has not been demonstrated. The most common antireflux procedure is a Nissen fundoplication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .) Gastropexy is performed if the stomach is unusually mobile after reduction. Successful laparoscopic repair has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is excellent following surgical repair of a type II hiatal hernia (which accounts for 95 percent of paraesophageal hernias). The recurrence rate for type II hernias is higher than for type I hernias presumably because the tissues of the hiatus are more compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/33/37393?source=see_link\">",
"       \"Patient information: Hiatal hernia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4040162\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hiatus hernia refers to herniation of elements of the abdominal cavity through the esophageal hiatus of the diaphragm. The most comprehensive classification scheme recognizes four types of hiatal hernia.",
"      <br/>",
"      <br/>",
"      Type I or sliding hiatal hernia accounts for more than 95 percent of cases. This type of hernia is characterized by widening of the muscular hiatal tunnel and circumferential laxity of the phrenoesophageal membrane, allowing a portion of the gastric cardia to herniate upward. The phrenoesophageal membrane remains intact and the hernia is contained within the posterior mediastinum (",
"      <a class=\"graphic graphic_figure graphicRef62190 \" href=\"UTD.htm?30/59/31671\">",
"       figure 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The less common types of hiatal hernia, types II, III, and IV, are varieties of \"paraesophageal\" hernias which account for about 5 percent of all hiatal hernias. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of hiatal hernia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hiatal hernia is usually discovered incidentally on upper gastrointestinal studies or endoscopy. Many patients with a type II hernia are either asymptomatic or have only vague, intermittent symptoms. The most common symptoms are epigastric or substernal pain, postprandial fullness, substernal fullness, nausea, and retching. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repair of an isolated, asymptomatic type I hiatal hernia is rarely indicated. If symptoms of gastroesophageal reflux disease occur in association with a large hiatus hernia, either medical or surgical treatment is indicated to control the reflux. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The enlarging types II, III, and IV hernias pose a risk of serious complications. However, prophylactic paraesophageal hernia repair is rarely performed, as the mortality rate from elective paraesophageal hernia repair is 1.4 percent, while the probability of developing acute symptoms requiring emergent surgery is 1.1 percent. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/1\">",
"      Pouderoux P, Lin S, Kahrilas PJ. Timing, propagation, coordination, and effect of esophageal shortening during peristalsis. Gastroenterology 1997; 112:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/2\">",
"      Kahrilas PJ, Wu S, Lin S, Pouderoux P. Attenuation of esophageal shortening during peristalsis with hiatus hernia. Gastroenterology 1995; 109:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/3\">",
"      Kahrilas PJ. Hiatus hernia causes reflux: Fact or fiction? Gullet 1993; 3(Suppl):21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/4\">",
"      Lin S, Brasseur JG, Pouderoux P, Kahrilas PJ. The phrenic ampulla: distal esophagus or potential hiatal hernia? Am J Physiol 1995; 268:G320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/5\">",
"      Paterson WG, Kolyn DM. Esophageal shortening induced by short-term intraluminal acid perfusion in opossum: a cause for hiatus hernia? Gastroenterology 1994; 107:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/6\">",
"      Liebermann-Meffert D, Allg&ouml;wer M, Schmid P, Blum AL. Muscular equivalent of the lower esophageal sphincter. Gastroenterology 1979; 76:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/7\">",
"      Weston AP. Hiatal hernia with cameron ulcers and erosions. Gastrointest Endosc Clin N Am 1996; 6:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/8\">",
"      Mittal RK, Rochester DF, McCallum RW. Sphincteric action of the diaphragm during a relaxed lower esophageal sphincter in humans. Am J Physiol 1989; 256:G139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/9\">",
"      Hill LD, Kozarek RA, Kraemer SJ, et al. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 1996; 44:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/10\">",
"      Hill LD, Kraemer SJ, Aye RW, et al. Laparoscopic Hill repair. Contemp Surg 1994; 44:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/11\">",
"      Kahrilas PJ, Kim HC, Pandolfino JE. Approaches to the diagnosis and grading of hiatal hernia. Best Pract Res Clin Gastroenterol 2008; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     Peridikis G, Hinder RA. Paraesophageal hiatal hernia. In: Hernia, Nyhus LM, Condon RE (Eds), JB Lippincott, Philadelphia 1995. p.544.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/13\">",
"      Ott DJ, Gelfand DW, Chen YM, et al. Predictive relationship of hiatal hernia to reflux esophagitis. Gastrointest Radiol 1985; 10:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/14\">",
"      Wright RA, Hurwitz AL. Relationship of hiatal hernia to endoscopically proved reflux esophagitis. Dig Dis Sci 1979; 24:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/15\">",
"      Boyle JT, Altschuler SM, Nixon TE, et al. Role of the diaphragm in the genesis of lower esophageal sphincter pressure in the cat. Gastroenterology 1985; 88:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/16\">",
"      Boyle JT, Altschuler SM, Nixon TE, et al. Responses of feline gastroesophageal junction to changes in abdominal pressure. Am J Physiol 1987; 253:G315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/17\">",
"      Mittal RK, Rochester DF, McCallum RW. Electrical and mechanical activity in the human lower esophageal sphincter during diaphragmatic contraction. J Clin Invest 1988; 81:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/18\">",
"      Mittal RK, Fisher M, McCallum RW, et al. Human lower esophageal sphincter pressure response to increased intra-abdominal pressure. Am J Physiol 1990; 258:G624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/19\">",
"      Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992; 117:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/20\">",
"      MICHELSON E, SIEGEL CI. THE ROLE OF THE PHRENICO-ESOPHAGEAL LIGAMENT IN THE LOWER ESOPHAGEAL SPHINCTER. Surg Gynecol Obstet 1964; 118:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/21\">",
"      Kahrilas PJ, Lin S, Chen J, Manka M. The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut 1999; 44:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/22\">",
"      Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 2003; 125:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/23\">",
"      Kahrilas PJ, Shi G, Manka M, Joehl RJ. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000; 118:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/24\">",
"      van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000; 119:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/25\">",
"      Johnson LF. 24-hour pH monitoring in the study of gastroesophageal reflux. J Clin Gastroenterol 1980; 2:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/26\">",
"      Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991; 100:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/27\">",
"      Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987; 92:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/28\">",
"      Davis SS Jr. Current controversies in paraesophageal hernia repair. Surg Clin North Am 2008; 88:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/29\">",
"      Menguy R. Surgical management of large paraesophageal hernia with complete intrathoracic stomach. World J Surg 1988; 12:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/30\">",
"      Stylopoulos N, Gazelle GS, Rattner DW. Paraesophageal hernias: operation or observation? Ann Surg 2002; 236:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/31\">",
"      Luketich JD, Nason KS, Christie NA, et al. Outcomes after a decade of laparoscopic giant paraesophageal hernia repair. J Thorac Cardiovasc Surg 2010; 139:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7527/abstract/32\">",
"      Wiechmann RJ, Ferguson MK, Naunheim KS, et al. Laparoscopic management of giant paraesophageal herniation. Ann Thorac Surg 2001; 71:1080.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2259 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7527=[""].join("\n");
var outline_f7_22_7527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4040162\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PHYSIOLOGY OF THE GASTROESOPHAGEAL JUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF HIATAL HERNIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type I: Sliding hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type II, III, and IV: Paraesophageal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Association of type I hiatus hernia with gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hiatus hernia and the diaphragmatic sphincter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Compromise of esophageal emptying related to hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4040162\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2259|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/1/42004\" title=\"diagnostic image 1\">",
"      Type I hiatal hernia UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/36/15939\" title=\"diagnostic image 2\">",
"      Type III hiatal hernia UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2259|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/18/42275\" title=\"figure 1\">",
"      Normal esophageal shortening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/2/36896\" title=\"figure 2\">",
"      Anatomy sliding hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/16/35087\" title=\"figure 3\">",
"      Gastric component of the LES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/59/31671\" title=\"figure 4\">",
"      Sliding versus paraesophageal hiatal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/36/37447\" title=\"figure 5\">",
"      Progression of hiatal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/59/27572\" title=\"figure 6\">",
"      Volvulus in hiatal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/15/3314\" title=\"figure 7\">",
"      HH and LES pressure on reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/56/16256\" title=\"figure 8\">",
"      Hiatal hernia and rereflux",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19128?source=related_link\">",
"      Paraesophageal hernia: Clinical features and surgical repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/33/37393?source=related_link\">",
"      Patient information: Hiatal hernia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_22_7528="Noninfectious complications of peritoneal dialysis catheters";
var content_f7_22_7528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninfectious complications of peritoneal dialysis catheters",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Rebecca J Schmidt, DO, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7528/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/22/7528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent and important complication of peritoneal dialysis catheters is infection, which may result in catheter loss and discontinuation of peritoneal dialysis (PD) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, some evidence suggests that the transfer to hemodialysis for these reasons may be decreasing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also significant noninfectious complications of PD catheters. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Outflow failure",
"     </li>",
"     <li>",
"      Pericatheter leak",
"     </li>",
"     <li>",
"      Abdominal wall herniation",
"     </li>",
"     <li>",
"      Catheter cuff extrusion",
"     </li>",
"     <li>",
"      Intestinal perforation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these complications can be managed conservatively; others require laparoscopic, peritoneoscopic, or traditional surgical intervention.",
"   </p>",
"   <p>",
"    This topic will review the causes, presentation, and management of outflow failure, pericatheter and pleuroperitoneal leaks, cuff extrusion, and visceral perforation. Other noninfectious complications of continuous peritoneal dialysis, such as gastroesophageal reflux disease, pain in the back and abdomen, abdominal wall herniation, and pleural effusion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22904?source=see_link\">",
"     \"Noninfectious complications of continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"     \"Abdominal hernias in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OUTFLOW FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outflow failure, which is defined as incomplete recovery of instilled dialysate, most commonly occurs because of one of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Constipation/obstipation",
"      </span>",
"     </li>",
"     <li>",
"      Catheter malposition",
"     </li>",
"     <li>",
"      Intraluminal catheter occlusion (often by thrombus)",
"     </li>",
"     <li>",
"      Extraluminal catheter occlusion (usually by omentum or adhesions)",
"     </li>",
"     <li>",
"      Catheter kinking",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of outflow failure ranges from 5 to 20 percent. Although the frequency is largely independent of the particular technique used for catheter insertion, peritoneoscopic placement may be associated with the fewest outflow complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/5-12\">",
"     5-12",
"    </a>",
"    ]. In one study, for example, only 10 outflow problems occurred among 136 peritoneoscopically placed catheters (8 percent) followed for 1183 patient-months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/12\">",
"     12",
"    </a>",
"    ]. One catheter had been placed in the preperitoneal space and nine had migrated because of misalignment of the radiopaque stripe (a feature that guides placement and maintains a clear view of catheter orientation).",
"   </p>",
"   <p>",
"    Another technique of catheter placement involves subcutaneous embedding of the peritoneal catheter for weeks to months in patients in whom the need for dialysis is not urgent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maximal chances for healing are desired [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/13\">",
"     13",
"    </a>",
"    ]. Since the wound surrounding the catheter site is allowed to heal, subcutaneous embedding may lower the frequency of catheter-related problems. The incidence of drainage failure, as well as other possible complications, was evaluated in one study of 26 such catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/14\">",
"     14",
"    </a>",
"    ]. Outflow failure occurred in five (20 percent). There was no correlation between omental obstruction and the duration of catheter embedding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outflow obstruction is frequently heralded by irregular outflow, fibrin in the dialysate outflow,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    constipation. Outflow obstruction in association with pain suggests catheter abutment; these patients have been found to have catheters positioned near discrete abdominal sites, such as the subdiaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outflow failure usually occurs within the first month of catheter use, with the time of onset varying by cause [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kinking of the catheter, which may cause inflow and outflow problems, usually becomes obvious soon after catheter placement. The degree of dysfunction may vary with patient position.",
"     </li>",
"     <li>",
"      Malpositioning causes of outflow failure are usually obvious within days of placement [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Omental occlusion is commonly observed within several weeks of catheter implantation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison,",
"    <span class=\"nowrap\">",
"     constipation/obstipation",
"    </span>",
"    is very common and may cause outflow obstruction at any period after the initiation of PD, and may occur in those who have undergone continuous therapy for an extended duration without outflow problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal radiograph can elucidate the cause of outflow failure, particularly in those with severe constipation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catheter malposition. Recently implanted catheters have a radiopaque stripe which permits radiographic visualization of the catheter tip; the tip should not migrate significantly over time [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since outflow failure is defined by the incomplete recovery of instilled fluid, it is important to exclude pericatheter or dialysate leakage as the underlying cause of the lost dialysate. The detection of dialysate leaking out of the abdominal cavity, whether internally or externally, is discussed below.",
"   </p>",
"   <p>",
"    If leakage has been excluded, the etiology of outflow failure can be ascertained by the history, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiography. As an example, a decrease in dialysate flow occurring days after catheter placement, in combination with a radiograph showing an abnormally placed catheter, strongly suggests that malpositioning is the underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is optimized by proper positioning of the catheter upon implantation and avoiding constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of outflow failure depends upon the cause of the obstruction. Some can be treated conservatively, while others require surgical intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laxatives, suppositories, or saline enemas can be used to treat constipation. Appropriate agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , non-polyethylene glycol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    and other non-magnesium, non-phosphorus-containing stool",
"    <span class=\"nowrap\">",
"     softener/laxative",
"    </span>",
"    combinations. The resumption of bowel movements cures nearly one-half of all cases of outflow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fibrin clot",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (at a dose of 200 to 500 units per liter) is usually added when plugs or strands of fibrin are visible in the drained fluid, it is more beneficial when added prophylactically. Occlusions due to fibrin clot were traditionally managed with urokinase-induced lysis, a procedure in which urokinase (5000 units) was instilled into the catheter for one hour and then removed. The effectiveness of this procedure varied between individuals and with the size and viscosity of the clot. If successful, lysis was followed by the instillation of heparin in the dialysate for several exchanges [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given its effectiveness in occluded central venous dialysis catheters,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA), a recombinant protease specific for fibrin, has been utilized in clotted peritoneal dialysis catheters, with some anecdotal success:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      , fibrin clot dissolution was achieved in four peritoneal dialysis patients with both inflow and outflow intracatheter obstruction refractory to saline flushes [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/17\">",
"       17",
"      </a>",
"      ]. Alteplase was instilled and allowed to dwell for an hour after which relief of obstruction was obtained.",
"     </li>",
"     <li>",
"      In another study, thrombolysis was effective in four of seven attempts after instillation and a one-hour dwell in catheters of six pediatric patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    will vary according to volume of the peritoneal dialysis catheter and its respective transfer set.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Malpositioned catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although malpositioned catheters frequently require replacement (particularly for long-term patency), they can sometimes be managed with fluoroscopy. Stiff wire manipulation can be performed by most interventional radiologists. With this technique, initial success with restoration of drain capability is observed in 55 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. However, long-term salvage is less reliable (33 percent), as repeated malpositioning is common. In addition, redirection can be performed surgically, including laparoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known whether the catheter design influences the risk of malposition. One randomized controlled trial that compared coiled versus straight end swan neck catheters found no significant differences in catheter malposition or non-infectious complications. However, in this study and in an accompanying meta-analysis that included the results of this study, there was a trend for an increased risk of catheter tip malposition with coiled end catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/26\">",
"     26",
"    </a>",
"    ]. Additional study of this is needed before a recommendation for a specific catheter can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Catheter kinking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kinking usually requires catheter replacement. However, since kinking may be due to the placement of the two catheter cuffs too near each other, removal of the superficial cuff may cure outflow problems [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Abdominal exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If initial management attempts fail",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional catheter manipulation or replacement is required, traditional surgical, peritoneoscopic, or laparoscopic exploration may be useful since they allow direct visualization of the peritoneal cavity. These techniques permit the operator, if necessary, to perform the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Catheter redirection",
"     </li>",
"     <li>",
"      Omentectomy or adhesiolysis",
"     </li>",
"     <li>",
"      Catheter replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An advantage of the less invasive surgical techniques is that catheter function can be tested immediately after an attempt at correction but prior to scope removal, thereby permitting additional corrective manipulations if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The effectiveness of laparoscopic surgery to salvage dysfunctional catheters was evaluated in one study of 16 patients who underwent 19 laparoscopic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/7\">",
"     7",
"    </a>",
"    ]. Adhesions were the cause of obstruction in 12 cases; omental wrapping in 7; and both adhesions and omental wrapping in one. All 19 salvage procedures were successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PERICATHETER LEAKAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leakage of dialysate at the pericatheter site tends to occur early after catheter placement, in association with high dialysate volumes, and in those with a weak abdominal wall (such as those with a history of multiple surgeries or pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/15,32,33\">",
"     15,32,33",
"    </a>",
"    ]. In addition, leaks frequently occur only after a patient becomes physically active on a standard ambulatory peritoneal dialysis regimen, a schedule in which dwells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exchanges occur in association with maximum intraabdominal pressures. They are therefore less common in those who undergo dialysate exchanges when supine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of pericatheter leak is widely variable (1 to 40 percent), due in part to varying outcomes with the three principal methods of catheter placement: surgical, peritoneoscopic, and percutaneous without peritoneoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/8-12,33-37\">",
"     8-12,33-37",
"    </a>",
"    ]. In one study, a higher incidence of leak was associated with the percutaneous approach compared with conventional surgical placement (20 versus 9 percent), although this difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/10\">",
"     10",
"    </a>",
"    ]. By comparison, earlier studies reported higher incidences of leak with surgical placement (12 to 39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/6,29,38,39\">",
"     6,29,38,39",
"    </a>",
"    ]. Leakage appears to be less likely with peritoneoscopically-placed catheters and presternal catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/27,40-42\">",
"     27,40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subcutaneous embedding of the implanted peritoneal catheter may be associated with a very low incidence of pericatheter leakage. In one study, 26 catheters were embedded subcutaneously for 28 to 675 days and 21 were ultimately activated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/14\">",
"     14",
"    </a>",
"    ]. No leaks occurred.",
"   </p>",
"   <p>",
"    The incidence of leakage for subcutaneous embedded catheters may be associated with the length of time the catheters are buried. One report found that no catheter buried for four or more weeks leaked while 16 percent of catheters activated less than four weeks after placement leaked, as did 14 percent of conventionally placed catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, it is not clear that one type of catheter is superior to another with regard to the potential for leakage; however, the double cuff catheter is generally considered least likely to be associated with leak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericatheter leakage is recognized by the presence of fluid in the area surrounding the catheter. However, the initial manifestations of pericatheter leakage may be subtle. Subcutaneous swelling, which may be overlooked, and diminished outflow volumes may precede frank leakage. Genital and abdominal wall edema may also indicate the presence of a subcutaneous leak. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"     \"Abdominal hernias in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fluid around a peritoneal catheter may be due to leakage of dialysate or to serosanguineous fluid extruding from the subcutaneous tissue. If the etiology of the fluid is unclear, a dialysate leak can be confirmed by checking the glucose concentration of the leaking fluid. Dextrostick testing will yield an extremely high glucose concentration if the fluid is dialysate. By comparison, serosanguineous fluid leaking from subcutaneous tissue will not be strongly positive for glucose.",
"   </p>",
"   <p>",
"    To help confirm the diagnosis and delineate the anatomy of the leak, peritoneal scintigraphy or, in particular, CT scanning after infusion of dialysate containing contrast material can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/33,44\">",
"     33,44",
"    </a>",
"    ]. In one retrospective study, one-third of leaks occurring late after catheter placement required imaging for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of pericatheter leaks can usually be accomplished by decreasing exertional activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the dialysate volume. Occasionally, converting the patient to continuous peritoneal modalities in which exchanges occur when supine or to temporary hemodialysis may resolve dialysate leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/46\">",
"     46",
"    </a>",
"    ]. Leaks that do not respond to conservative management may require minor surgical repair of the deep cuff or rarely catheter replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CATHETER CUFF EXTRUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erosion of the catheter cuff through the skin to the outer abdominal wall may be a sequela of exit-site infection or excessive superficial cuff placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cuff extrusion ranges from 3.5 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/16,29,38,39,43\">",
"     16,29,38,39,43",
"    </a>",
"    ]. Neither the method of catheter placement, surgical or percutaneous, nor the specific catheter used influences the likelihood of extrusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/16,29,38,43,47\">",
"     16,29,38,43,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for cuff shaving or catheter removal depends in part upon the presence or absence of infection. More conservative measures may be attempted in those without evidence of an infectious process. An eroding, extruding cuff may require removal by opening the subcutaneous tissue surrounding the exit site and trimming the cuff under sterile conditions and local anesthesia. Poor healing of the area or signs of persistent inflammation or infection are indications for catheter removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INTESTINAL PERFORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal perforation can occur at the time of catheter implantation because of direct injury, or weeks to months after placement because of bowel erosion. This complication can be life-threatening and therefore requires a high index of suspicion and urgent attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal perforation by peritoneal dialysis catheters is uncommon (1 percent or less) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/6,9-11,16,37,48\">",
"     6,9-11,16,37,48",
"    </a>",
"    ]. This incidence is largely independent of the type of placement, but may be more common with the placement of semirigid acute PD catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clues to the presence of perforation are feculent or bloody dialysate, dialysate retention, diarrhea occurring after dialysate instillation, or gram-negative peritonitis. Diarrhea resulting from perforation may be diagnosed by noting a very high glucose concentration in the stool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy consists of the cessation of peritoneal dialysis treatments, catheter removal, intravenous antibiotics, and bowel repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding which occurs soon after catheter placement is most often due to trauma of small blood vessels located in the abdominal wall. The incidence of this complication was reported in a retrospective review of 292 catheters placed in 263 patients between the years 1992 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/49\">",
"     49",
"    </a>",
"    ]. Six patients had major bleeding (2 percent), which occurred in association with perioperative anticoagulation (3 patients), intraoperative bleeding (one patient), thrombocytopenia and uremia (one), and thrombocytopenia and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use (one). Based on these observations, preventive measures should include holding anticoagulation therapy for a minimum of 24 hours after the procedure and obtaining and (if necessary) correcting coagulation parameters prior to surgery.",
"   </p>",
"   <p>",
"    Unless the effluent hematocrit is greater than two percent, conservative management with ongoing observation is safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7528/abstract/15\">",
"     15",
"    </a>",
"    ]. In this setting, heparinization of the dialysate can be used to prevent catheter occlusion.",
"   </p>",
"   <p>",
"    Hemoperitoneum not temporally related to catheter placement can also occur and is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22904?source=see_link\">",
"     \"Noninfectious complications of continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=see_link\">",
"     \"Bloody peritoneal dialysate (hemoperitoneum)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ABDOMINAL SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major abdominal surgery that is unrelated to the catheter is sometimes required in patients with an indwelling peritoneal dialysis catheter. In this setting, surgery may be complicated by the presence of dense intra-abdominal adhesions (due in part to repeated peritonitis episodes), and the presence of the catheter in the upper or lower abdomen, or pelvis.",
"   </p>",
"   <p>",
"    Given that many patients have minimal adhesions, the presence of an intraperitoneal catheter is not a contraindication to laparoscopy; the surgeon should be prudent and employ an open insertion of the trocar. With planned open procedures, the possible need for extensive adhesiolysis should be anticipated.",
"   </p>",
"   <p>",
"    The abdominal incision should not be near the catheter insertion site. In addition, the catheter should be identified to ensure that it is not displaced during packing or manipulation of abdominal contents.",
"   </p>",
"   <p>",
"    At completion of surgery, the catheter is checked to ensure it has not been dislodged; care should also be taken in closing the abdomen to avoid trapping the catheter in sutures.",
"   </p>",
"   <p>",
"    Hemodialysis may be required in the immediate post-operative period depending upon the patient's clinical status, degree of residual renal function, and ability to perform supine only, low volume PD exchanges. If interim hemodialysis is required, resumption of peritoneal dialysis after a week delay is reasonable, although the time on hemodialysis, time on low volume supine peritoneal dialysis, or time without dialysis, is variable based upon patient characteristics and the clinical situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although less frequent than infection, non-infectious complications of peritoneal dialysis catheters also occur. These include outflow failure, pericatheter leak, abdominal wall herniation, catheter cuff excursion and intestinal perforation. Some of these complications can be managed conservatively, while others require laparoscopic, peritoneoscopic or traditional surgical intervention. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outflow failure is commonly caused by constipation or obstipation. Radiography is useful for elucidating the cause of outflow failure especially if related to constipation or catheter malposition. It is important to exclude pericatheter or dialysate leakage as the underlying cause of incomplete recovery of instilled dialysate. Once leakage has been excluded, the underlying cause of outflow failure is usually ascertained by history, physical exam",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiography. Prevention is optimized by proper positioning of the catheter upon implantation and avoidance of constipation. Treatment of outflow failure depends on the cause of obstruction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Outflow failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericatheter leakage tends to occur early after catheter placement in association with high dialysate volumes and in those with weak abdominal walls. The incidence is widely variable and may relate to the practice of subcutaneous embedding of the implanted catheter upon implantation. Pericatheter leakage is recognized by the presence of fluid surrounding the catheter and may be initially subtle. Subcutaneous swelling and diminished outflow volumes may precede frank leakage. The diagnosis of pericatheter leakage may be made by a high glucose concentration of the leaking fluid. Confirmatory diagnosis and delineation of the anatomy of the leak may be demonstrated more definitively by CT scanning. Management is usually accomplished successfully by decreasing either dialysate volume",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exertional activity. Temporary transfer to continuous peritoneal dialysis or temporary hemodialysis may be necessary in some patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pericatheter leakage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erosion of the catheter cuff through the skin may be a sequela of exit-site infection or excessive superficial cuff placement. Conservative measures may be attempted in those without evidence of an infectious process. Cuff shaving or catheter removal may be required in the presence of infection. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Catheter cuff extrusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intestinal perforation can occur at the time of catheter implantation because of direct injury, or weeks to months after placement because of bowel erosion. This complication can be life-threatening and therefore requires a high index of suspicion and urgent attention. Clues to the presence of perforation are feculent or bloody dialysate, dialysate retention, diarrhea occurring after dialysate instillation, or gram-negative peritonitis. Therapy consists of the cessation of peritoneal dialysis treatments, catheter removal, intravenous antibiotics, and bowel repair. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Intestinal perforation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/1\">",
"      Holley, HL, Piraino, BM. Complications of peritoneal dialysis: Diagnosis and management. Semin Dial 1990; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/2\">",
"      Bender FH. Avoiding harm in peritoneal dialysis patients. Adv Chronic Kidney Dis 2012; 19:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/3\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/4\">",
"      McCormick BB, Bargman JM. Noninfectious complications of peritoneal dialysis: implications for patient and technique survival. J Am Soc Nephrol 2007; 18:3023.",
"     </a>",
"    </li>",
"    <li>",
"     Leehey, DJ, Ash, SR, Daugirdas, JT. Complications other than peritonitis Peritoneal access devices. In: Handbook of Dialysis, Daugirdas, JT, Blake, PG, Ing, TS (Eds), Little, Brown, Boston, 1994, p. 363 Lippincott, Williams &amp; Wilkins, Philadephia 2007. p.36.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/6\">",
"      Fleisher AG, Kimmelstiel FM, Lattes CG, Miller RE. Surgical complications of peritoneal dialysis catheters. Am J Surg 1985; 149:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/7\">",
"      Kimmelstiel FM, Miller RE, Molinelli BM, Lorch JA. Laparoscopic management of peritoneal dialysis catheters. Surg Gynecol Obstet 1993; 176:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/8\">",
"      Allon M, Soucie JM, Macon EJ. Complications with permanent peritoneal dialysis catheters: experience with 154 percutaneously placed catheters. Nephron 1988; 48:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/9\">",
"      Adamson AS, Kelleher JP, Snell ME, Hulme B. Endoscopic placement of CAPD catheters: a review of one hundred procedures. Nephrol Dial Transplant 1992; 7:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/10\">",
"      Mellotte GJ, Ho CA, Morgan SH, et al. Peritoneal dialysis catheters: a comparison between percutaneous and conventional surgical placement techniques. Nephrol Dial Transplant 1993; 8:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/11\">",
"      Nahman NS Jr, Middendorf DF, Bay WH, et al. Modification of the percutaneous approach to peritoneal dialysis catheter placement under peritoneoscopic visualization: clinical results in 78 patients. J Am Soc Nephrol 1992; 3:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/12\">",
"      Copley JB, Lindberg JS, Back SN, Tapia NP. Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Perit Dial Int 1996; 16 Suppl 1:S330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/13\">",
"      Moncrief, JW, Popovich, RP, Moncrief, B, et al. Moncrief-Popovich catheter: A new access technique for patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/14\">",
"      Prischl FC, Wallner M, Kalchmair H, et al. Initial subcutaneous embedding of the peritoneal dialysis catheter--a critical appraisal of this new implantation technique. Nephrol Dial Transplant 1997; 12:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/15\">",
"      Farooq MM, Freischlag JA. Peritoneal dialysis: an increasingly popular option. Semin Vasc Surg 1997; 10:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/16\">",
"      Robison RJ, Leapman SB, Wetherington GM, et al. Surgical considerations of continuous ambulatory peritoneal dialysis. Surgery 1984; 96:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/17\">",
"      Sahani MM, Mukhtar KN, Boorgu R, et al. Tissue plasminogen activator can effectively declot peritoneal dialysis catheters. Am J Kidney Dis 2000; 36:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/18\">",
"      Shea M, Hmiel SP, Beck AM. Use of tissue plasminogen activator for thrombolysis in occluded peritoneal dialysis catheters in children. Adv Perit Dial 2001; 17:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/19\">",
"      Jaques P, Richey W, Mandel S. Tenckhoff peritoneal dialysis catheter: cannulography and manipulation. AJR Am J Roentgenol 1980; 135:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/20\">",
"      Moss JS, Minda SA, Newman GE, et al. Malpositioned peritoneal dialysis catheters: a critical reappraisal of correction by stiff-wire manipulation. Am J Kidney Dis 1990; 15:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/21\">",
"      Dobrashian RD, Conway B, Hutchison A, et al. The repositioning of migrated Tenckhoff continuous ambulatory peritoneal dialysis catheters under fluoroscopic control. Br J Radiol 1999; 72:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/22\">",
"      Simons ME, Pron G, Voros M, et al. Fluoroscopically-guided manipulation of malfunctioning peritoneal dialysis catheters. Perit Dial Int 1999; 19:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/23\">",
"      McLaughlin K, Jardine AG. Closed stiff-wire manipulation of malpositioned Tenckhoff catheters offers a safe and effective way of prolonging peritoneal dialysis. Int J Artif Organs 2000; 23:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/24\">",
"      Miller M, McCormick B, Lavoie S, et al. Fluoroscopic manipulation of peritoneal dialysis catheters: outcomes and factors associated with successful manipulation. Clin J Am Soc Nephrol 2012; 7:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/25\">",
"      Yilmazlar T, Kirdak T, Bilgin S, et al. Laparoscopic findings of peritoneal dialysis catheter malfunction and management outcomes. Perit Dial Int 2006; 26:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/26\">",
"      Xie J, Kiryluk K, Ren H, et al. Coiled versus straight peritoneal dialysis catheters: a randomized controlled trial and meta-analysis. Am J Kidney Dis 2011; 58:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/27\">",
"      Ash, SR. Chronic peritoneal dialysis catheters: Effects of catheter design, materials, and location. Semin Dial 1990; 3:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/28\">",
"      Owens LV, Brader AH. Laparoscopic salvage of Tenckhoff catheters. Surg Endosc 1995; 9:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/29\">",
"      Cronen PW, Moss JP, Simpson T, et al. Tenckhoff catheter placement: surgical aspects. Am Surg 1985; 51:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/30\">",
"      Zadrozny D, Lichodziejewska-Niemierko M, Draczkowski T, et al. Laparoscopic approach for dysfunctional Tenckhoff catheters. Perit Dial Int 1999; 19:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/31\">",
"      Goh YH. Omental folding: a novel laparoscopic technique for salvaging peritoneal dialysis catheters. Perit Dial Int 2008; 28:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/32\">",
"      Newman LN, Tessman M, Hanslik T, et al. A retrospective view of factors that affect catheter healing: four years of experience. Adv Perit Dial 1993; 9:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/33\">",
"      Leblanc M, Ouimet D, Pichette V. Dialysate leaks in peritoneal dialysis. Semin Dial 2001; 14:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/34\">",
"      Eklund BH. Surgical implantation of CAPD catheters: presentation of midline incision-lateral placement method and a review of 110 procedures. Nephrol Dial Transplant 1995; 10:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/35\">",
"      Cruz C. Cruz catheter: implantation technique and clinical results. Perit Dial Int 1994; 14 Suppl 3:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/36\">",
"      Pastan S, Gassensmith C, Manatunga AK, et al. Prospective comparison of peritoneoscopic and surgical implantation of CAPD catheters. ASAIO Trans 1991; 37:M154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/37\">",
"      Bullmaster JR, Miller SF, Finley RK Jr, Jones LM. Surgical aspects of the Tenckhoff peritoneal dialysis catheter. A 7 year experience. Am J Surg 1985; 149:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/38\">",
"      Swartz RD. Chronic peritoneal dialysis: mechanical and infectious complications. Nephron 1985; 40:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/39\">",
"      Swartz R, Messana J, Rocher L, et al. The curled catheter: dependable device for percutaneous peritoneal access. Perit Dial Int 1990; 10:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/40\">",
"      Gadallah MF, Pervez A, el-Shahawy MA, et al. Peritoneoscopic versus surgical placement of peritoneal dialysis catheters: a prospective randomized study on outcome. Am J Kidney Dis 1999; 33:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/41\">",
"      Vaux EC, Torrie PH, Barker LC, et al. Percutaneous fluoroscopically guided placement of peritoneal dialysis catheters--a 10-year experience. Semin Dial 2008; 21:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/42\">",
"      Yerram P, Gill A, Prowant B, et al. A 9-year survival analysis of the presternal Missouri swan-neck catheter. Adv Perit Dial 2007; 23:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/43\">",
"      de Alvaro F, Selgas R, Bajo MA, et al. Moncrief's technique for peritoneal catheter placement: experience of a CAPD unit. Adv Perit Dial 1994; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/44\">",
"      Stuart S, Booth TC, Cash CJ, et al. Complications of continuous ambulatory peritoneal dialysis. Radiographics 2009; 29:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/45\">",
"      Tzamaloukas AH, Gibel LJ, Eisenberg B, et al. Early and late peritoneal dialysate leaks in patients on CAPD. Adv Perit Dial 1990; 6:64.",
"     </a>",
"    </li>",
"    <li>",
"     Ash, SR, Daugirdas, JT. Peritoneal dialysis access. In: Handbook of Dialysis, Daugirdas, JT, Ing, TS (Eds), Little, Brown, Boston 1994. p.274.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/47\">",
"      Twardowski ZJ, Prowant BF, Khanna R, et al. Long-term experience with Swan Neck Missouri catheters. ASAIO Trans 1990; 36:M491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/48\">",
"      Asif A, Byers P, Vieira CF, et al. Peritoneoscopic placement of peritoneal dialysis catheter and bowel perforation: experience of an interventional nephrology program. Am J Kidney Dis 2003; 42:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7528/abstract/49\">",
"      Mital S, Fried LF, Piraino B. Bleeding complications associated with peritoneal dialysis catheter insertion. Perit Dial Int 2004; 24:478.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1883 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-5866CBA7F6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7528=[""].join("\n");
var outline_f7_22_7528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OUTFLOW FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Constipation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fibrin clot",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Malpositioned catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Catheter kinking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Abdominal exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PERICATHETER LEAKAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CATHETER CUFF EXTRUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INTESTINAL PERFORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ABDOMINAL SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=related_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=related_link\">",
"      Bloody peritoneal dialysate (hemoperitoneum)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22904?source=related_link\">",
"      Noninfectious complications of continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=related_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=related_link\">",
"      Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_22_7529="First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18";
var content_f7_22_7529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Jacob A Canick, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Geralyn M Messerlian, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Antonio Farina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7529/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/22/7529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;First trimester and integrated screening tests for Down syndrome and trisomy 18 will be reviewed here. Other aspects of Down syndrome screening are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"       \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=see_link\">",
"       \"Second trimester maternal serum screening for Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27257?source=see_link\">",
"       \"Laboratory issues related to maternal serum screening for Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"       \"Sonographic findings associated with fetal aneuploidy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A glossary of terms describing the various tests used in first and second trimester screening for Down syndrome is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef76911 \" href=\"UTD.htm?34/33/35355\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIRST TRIMESTER COMBINED TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are obvious advantages to performing Down syndrome screening early in pregnancy. Early diagnosis of fetal abnormalities allows the couple maximum time for decision making; privacy, since others may not be aware of the pregnancy; and, if chosen, safer methods of pregnancy termination.",
"   </p>",
"   <p>",
"    First trimester Down syndrome screening is done in the late first trimester, between",
"    <span class=\"nowrap\">",
"     9",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation, depending on which markers are used (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Timing of blood sample and ultrasound'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/1\">",
"     1",
"    </a>",
"    ]. The first trimester screening test consists of three markers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal serum beta human chorionic gonadotropin (beta-hCG)",
"     </li>",
"     <li>",
"      Maternal serum pregnancy-associated plasma protein-A (PAPP-A)",
"     </li>",
"     <li>",
"      Ultrasound measurement of nuchal translucency (NT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three markers comprise the \"combined test\" and together with maternal age provide a patient-specific risk [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The combined test detects approximately 85 percent of Down syndrome (ie, detection rate [DR] = sensitivity = 85 percent) with a false positive rate (FPR) of 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/3,7-16\">",
"     3,7-16",
"    </a>",
"    ]. As described below, it can also detect trisomy 18 (",
"    <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"     table 2",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H17\">",
"     'Trisomy 18 risk assessment'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The combined test performs slightly better than the second trimester quadruple test (ie, the DR is higher",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the FPR is lower). This comparison has been calculated after adjustment for the expected natural losses of Down syndrome fetuses between the first and second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is arguable whether the combined test is a cost effective screening approach [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. Its cost is highly dependent upon ultrasound charges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Timing of blood sample and ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood tests and ultrasound examination for the combined test are most commonly performed between",
"    <span class=\"nowrap\">",
"     11",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16165428\">",
"    <span class=\"h3\">",
"     Beta-HCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-HCG levels are, on average, elevated in pregnancies affected with fetal Down syndrome. Beta-hCG can be assayed in its free or total form.",
"   </p>",
"   <p>",
"    Free beta-hCG is effective at",
"    <span class=\"nowrap\">",
"     9",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks, and the performance improves as gestational age advances within this interval [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total beta-hCG is effective at",
"    <span class=\"nowrap\">",
"     11",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks, and the performance improves as gestational age advances within this interval [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/7,8,17\">",
"     7,8,17",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Between",
"    <span class=\"nowrap\">",
"     11",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks, there is no consensus as to whether free beta-hCG performs significantly better than total beta-hCG for Down syndrome screening when interpreted in conjunction with measurement of PAPP-A and nuchal translucency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/7,8,21\">",
"     7,8,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16165436\">",
"    <span class=\"h3\">",
"     PAPP-A",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAPP-A is a complex, high molecular weight glycoprotein. Its levels, on average, are lower in pregnancies affected with fetal Down syndrome. In contrast to beta-hCG, PAPP-A performance as a screening marker decreases with increasing gestational age between 9 and 13 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/8,17,18,22\">",
"     8,17,18,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16165460\">",
"    <span class=\"h3\">",
"     Nuchal translucency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal NT thickness measured between",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    gestational weeks is, on average, increased in fetuses with Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/9,23,24\">",
"     9,23,24",
"    </a>",
"    ]. NT performance as a screening marker decreases with advancing gestation between 10 and 13 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/18,25,26\">",
"     18,25,26",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Performance of NT as a screening marker has not been consistent from study to study, presumably because of variability in operator expertise and quality of equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/5,9,24,27-29\">",
"     5,9,24,27-29",
"    </a>",
"    ]. For this reason, proper training and ongoing quality management are essential components of screening programs that involve measurement of nuchal translucency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=see_link\">",
"     \"First trimester cystic hygroma and increased nuchal translucency\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Fetuses with a cystic hygroma or significantly enlarged nuchal translucency are at particularly high risk of aneuploidy. Many experts proceed directly to karyotype assessment in these cases, rather than checking maternal serum analyte levels. The optimum threshold for proceeding to karyotype assessment without maternal serum screening is unclear. Nuchal translucency thresholds in the range of 3.0 to 4.0 mm have been suggested, given the relatively high risk of Down syndrome at this level. Enlarged nuchal translucency has also been associated with other structural malformations. This topic is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=see_link\">",
"     \"First trimester cystic hygroma and increased nuchal translucency\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Additional sonographic findings in Down syndrome fetuses, including the second trimester genetic sonogram, are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16165467\">",
"    <span class=\"h3\">",
"     Inhibin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibin-A is also an effective Down syndrome marker between",
"    <span class=\"nowrap\">",
"     11",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    gestational weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/7,8,17,31\">",
"     7,8,17,31",
"    </a>",
"    ]. Its levels are, on average, elevated in pregnancies affected with fetal Down syndrome. At this time, however, few programs use inhibin A in first trimester Down syndrome screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTEGRATED TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrated testing uses markers measured in both the first and second trimesters to provide a single estimate of risk for Down syndrome pregnancy. In the first trimester, a serum sample is assayed for PAPP-A between 9 and 13 weeks and an ultrasound measurement of NT, along with estimation of gestational age by crown-rump length, is performed between 10 and 13 weeks. The information is kept on file until a second trimester serum sample is drawn and the quadruple test markers are run (alpha fetoprotein [AFP], unconjugated estriol [uE3], inhibin A, beta-hCG) (",
"    <a class=\"graphic graphic_table graphicRef76911 \" href=\"UTD.htm?34/33/35355\">",
"     table 1",
"    </a>",
"    ). Beta-hCG can be used as a marker in either the first or second trimester, but is routinely measured in the second trimester when its performance is better.",
"   </p>",
"   <p>",
"    The six marker values are used, together with maternal age, to calculate a single risk for Down syndrome and a report is generated. The integrated test achieves an 85 percent DR at a 1 percent FPR. If a 90 percent DR is the target, the FPR will be 2 percent (",
"    <a class=\"graphic graphic_table graphicRef57348 \" href=\"UTD.htm?40/29/41436\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantage of the integrated test is that at an equivalent DR, it has a substantially lower FPR than the combined or quadruple test [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/32\">",
"     32",
"    </a>",
"    ]. A reduction in the FPR in screening tests is highly desirable. Any reduction in false positives while maintaining a high DR will increase the safety of the screening process because there will be fewer procedure-related miscarriages per Down syndrome pregnancy identified. A lower FPR will also decrease the number of patients who are anxious due to a false positive result; such anxiety appears to decrease participation in Down syndrome screening in the next pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disadvantage of the integrated test is that final test results are not available until the second trimester. This problem can be mitigated by using a sequential approach, either step-wise or contingent (see below).",
"   </p>",
"   <p>",
"    Like the combined test, the integrated test can also detect trisomy 18, which is associated with a different pattern of test results (",
"    <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"     table 2",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H17\">",
"     'Trisomy 18 risk assessment'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serum integrated test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum integrated test is the same as the full integrated test, but without ultrasound measurement of nuchal translucency. This test provides an option to patients in areas where expertise in measurement of nuchal translucency is not available. It has the highest detection rate among screening tests that do not include nuchal translucency measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Step-wise sequential screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The step-wise sequential screening process involves performing the first trimester portion of the integrated screen and then offering counseling and chorionic villus sampling (CVS) to women whose results place them at very high risk (eg, &ge;1 in 50) of an affected fetus. Women whose screen does not place them at very high risk do not receive early results and go on to complete the second trimester portion of the test. The rationale for not releasing first trimester risk results to patients in the screen negative group is that this information may lead to diagnostic testing in those not at high risk and increase the observed FPR of the step-wise sequential test.",
"   </p>",
"   <p>",
"    One investigator estimated an 86 percent DR was achieved at a 2 percent FPR in a step-wise sequential test in which the first trimester cut-off for offering invasive testing was set at 1 in 40 and the integrated cut-off was set at 1 in 110 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/34\">",
"     34",
"    </a>",
"    ]. In the FASTER trial discussed below, step-wise sequential screening detected 95 percent of Down syndrome fetuses with a FPR of 5 percent (2.5 percent in the first trimester portion and 2.5 percent in the integrated portion of the test) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/18\">",
"     18",
"    </a>",
"    ]. These rates approach those of full integrated screening, but have the benefit of availability of early results for the highest risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/1\">",
"     1",
"    </a>",
"    ]. Issues related to this type of step-wise sequential testing have been reviewed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/32,34\">",
"     32,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reporting a first trimester Down syndrome risk and a separate and independent second trimester Down syndrome risk is not appropriate practice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The problems of independent sequential screening were illustrated in a multicenter study of the first trimester combined test sponsored by the National Institute of Child Health and Human Development [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/35\">",
"     35",
"    </a>",
"    ]. Independent first and second trimester sequential testing (the results of first trimester screening were not incorporated into the total risk assessment) resulted in a very high detection rate (overall about 98 percent), but at an inappropriately high FPR (about 17 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Contingent sequential screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contingent sequential screening is an approach in which three groups are identified based on risk [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;(1) women at very high risk (eg, &gt;1 in 50) of having a fetus with Down syndrome after first trimester testing would be offered immediate invasive prenatal diagnosis,",
"   </p>",
"   <p>",
"    &nbsp;(2) women at low risk (eg, &lt;1 in 2000) after first trimester testing would be provided with their risk estimate and would not undergo any additional testing, and",
"   </p>",
"   <p>",
"    &nbsp;(3) women at intermediate risk (in this example, between 1 in 50 and 1 in 2000) would have a second trimester blood draw to complete the integrated test [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In theory, this model provides an early result in most pregnancies for only a small increase in the overall FPR compared to the integrated test and may be a cost-effective approach [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/20,39-42\">",
"     20,39-42",
"    </a>",
"    ]. The women at intermediate risk may also be considered an \"interim\" screen positive group because they have been alerted to the need for additional testing. There is no consensus on which thresholds should be chosen for high and low risk after first trimester testing, which also has a major effect on cost-effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/42\">",
"     42",
"    </a>",
"    ]. Further analysis of appropriate risk cut-offs and issues of patient compliance are required before this method should be considered for routine clinical testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPARATIVE DATA FROM PROSPECTIVE TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Serum, Urine and Ultrasound Screening Study (SURUSS) and First and Second Trimester Evaluation of Risk (FASTER) trial evaluated Down syndrome screening in both the first and second trimesters of the same woman. A summary of results from these trials, including FPRs for various DRs, is provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef57348 \" href=\"UTD.htm?40/29/41436\">",
"     table 3",
"    </a>",
"    ). The trials are described in more detail below.",
"   </p>",
"   <p>",
"    Based on these results, women can be informed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The full integrated test (first trimester NT, PAPP-A, and second trimester AFP, uE3, beta-hCG, and inhibin A) is the most efficient screening test (high DR, low FPR). The rate of procedure-related unaffected fetal loss would be 9 per 100,000 women screened compared to about 45 such losses when either the combined test or a second trimester quadruple test is performed.",
"     </li>",
"     <li>",
"      If NT testing is not available, the serum integrated test (first trimester PAPP-A and second trimester AFP, uE3, beta-hCG, and inhibin A) is the next most efficient choice.",
"     </li>",
"     <li>",
"      The quadruple test (second trimester AFP, uE3, beta-hCG, and inhibin A) is the best available option for women who present for prenatal care in the second trimester.",
"     </li>",
"     <li>",
"      First trimester combined screening (NT, PAPP-A and beta-hCG) is a reasonable approach for women who desire earliest possible screening and diagnosis. Stepwise sequential screening, a variant of the integrated test, approximates the performance of the full integrated test and may be a valuable alternative because it reports very high risk results in the first trimester.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     The SURUSS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objective of SURUSS was to identify the most effective and safe method of antenatal screening for Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Twenty-five maternity units, primarily in the United Kingdom, collected data on over 47,000 screened singleton pregnancies, including 101 affected by Down syndrome. All NT data were analyzed, and nested case control sample sets were developed for analysis of all possible serum and urine markers and combinations.",
"   </p>",
"   <p>",
"    At a DR of 85 percent, the false positive rates were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First trimester combined test &ndash; 4.3 percent",
"     </li>",
"     <li>",
"      First and second trimester serum integrated test &ndash; 3.9 percent",
"     </li>",
"     <li>",
"      First and second trimester fully integrated test (includes NT) &ndash; 0.9 percent",
"     </li>",
"     <li>",
"      Second trimester quadruple test - 6.2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The odds of Down syndrome after a positive test based on data from the SURUSS trial are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef54782 \" href=\"UTD.htm?28/52/29515\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     The FASTER trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar results were reported by the FASTER Trial, which analyzed outcomes of over 38,000 women with singleton pregnancies at 15 centers in the United States who underwent both first trimester",
"    <span class=\"nowrap\">",
"     (10",
"     <sup>",
"      3/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     13",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks) and second trimester (15 to 18 weeks) screening for Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/18\">",
"     18",
"    </a>",
"    ]. Ninety-two affected pregnancies were found among the women that completed the screening protocol.",
"   </p>",
"   <p>",
"    At a DR of 85 percent, the false positive rates were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First trimester combined test - 4.8 percent",
"     </li>",
"     <li>",
"      First and second trimester serum integrated test - 4.4 percent",
"     </li>",
"     <li>",
"      First and second trimester fully integrated test (includes NT) - 0.8 percent",
"     </li>",
"     <li>",
"      Second trimester quadruple test - 7.3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In subgroup analysis of women &ge;35 years of age, first trimester combined screening had a DR of 95 percent with a FPR of 22 percent; for the integrated test, the results were 91 and 2 percent, respectively. For women under age 35, first trimester combined screening had a DR of 75 percent with a FPR of 5 percent; for the integrated test, the results were 77 and 0.4 percent, respectively (",
"    <a class=\"graphic graphic_table graphicRef75847 \" href=\"UTD.htm?38/57/39835\">",
"     table 5",
"    </a>",
"    ). A small decrease in screening performance between 11 and 13 weeks of gestation was observed.",
"   </p>",
"   <p>",
"    Women with a first trimester finding of septated cystic hygroma on initial ultrasound were excluded from the FASTER trial. The finding of septated cystic hygroma in the first trimester was associated with a 50 percent risk of aneuploidy. Nuchal translucency &ge;3 mm was associated with a 17 percent risk of aneuploidy, therefore, these findings warranted immediate diagnostic work-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=see_link\">",
"     \"First trimester cystic hygroma and increased nuchal translucency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Screen positive first trimester combined test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's risk of having an affected child is calculated from her age and screening test results and provided in the report (eg, Down syndrome risk 1 in 90). This number should be given to the patient.",
"   </p>",
"   <p>",
"    A positive screening test refers to a result showing that the woman's risk of having a child with Down syndrome is equal to, or exceeds, a specific cut-off level predetermined by the performance characteristics of the screening test. A typical cut-off for the combined test is the term risk of Down syndrome of &ge;1 in 300. This is associated with a FPR of about 5 percent and odds of Down syndrome of about 1 in 20. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27257?source=see_link&amp;anchor=H20#H20\">",
"     \"Laboratory issues related to maternal serum screening for Down syndrome\", section on 'Effect of maternal age'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a positive screening test, it is helpful to have a genetic counselor meet with the parents to inform them of their diagnostic and management options, including information about the natural history of Down syndrome. Nondirective information enables the parents to balance the risks, limitations, and benefits of prenatal screening and diagnostic testing with the medical, educational and social issues involved in raising a child with Down syndrome or pregnancy termination.",
"   </p>",
"   <p>",
"    Women with positive screening results are offered definitive fetal karyotype determination by chorionic villus sampling (CVS). First trimester combined and stepwise sequential testing should not be offered if CVS is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/36\">",
"     36",
"    </a>",
"    ]. Alternatively, they may choose to undergo secondary screening using a maternal plasma-based test for cell-free fetal DNA. Although not diagnostic, the high sensitivity and specificity of this test will reassure many of these women and allow them to avoid the risk associated with an invasive diagnostic test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H13809396#H13809396\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Secondary screening by a maternal plasma based test for fetal DNA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Screen positive integrated test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive test result means the patient's risk of having a baby with Down syndrome is greater than a specified cut-off level; it does not provide a definitive diagnosis of Down syndrome. The cut-off chosen for screen positive in the integrated test is often higher than that of the combined or quadruple test in order to take advantage of this test's low FPR. A typical cut-off for the integrated test is a midpregnancy risk of Down syndrome of &ge;1 in 100. This is associated with a FPR of 1 to 2 percent and odds of Down syndrome of about 1 in 5 to 1 in 10.",
"   </p>",
"   <p>",
"    The same counseling issues that apply to women with first trimester screen positive results are applicable to those with a screen positive integrated test result, except that amniocentesis is the diagnostic test offered instead of CVS since the screening result is provided in the early second trimester. Alternatively, as discussed above, they may choose to undergo secondary screening using a maternal plasma-based test for cell-free fetal DNA. Although not diagnostic, the high sensitivity and specificity of this test will reassure many of these women and allow them to avoid the risk associated with an invasive diagnostic test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H13809396#H13809396\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Secondary screening by a maternal plasma based test for fetal DNA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Screen negative first trimester or integrated test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A negative test result means the patient's risk of having a baby with Down syndrome is less than a specified cut-off level; it does not exclude the possibility of Down syndrome. The patient's risk is provided in the report (eg, Down syndrome risk 1 in 900) and this number should be given to the patient. With regard to Down syndrome screening, no further testing is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Detection of structural anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A first trimester screen or karyotype result does not obviate the need for second trimester fetal assessment, including second trimester ultrasound examination or AFP screening for neural tube defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sonographic evaluation for detection of fetal structural anomalies is commonly performed in the second trimester, although not the standard of care in many areas. If this examination is planned, it should be performed at 18 to 20 weeks for optimal visualization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TRISOMY 18 RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trisomy 18 occurs in about 1 in 8000 births. The prevalence is three to five-fold higher in the first and second trimesters than at birth because many affected fetuses die in utero. Ninety percent of affected infants die within the first year of life, 50 percent die within the first week. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11#H11\">",
"     \"Congenital cytogenetic abnormalities\", section on 'Trisomy 18 syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     First trimester combined test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first trimester analyte pattern characteristic of trisomy 18 is a very low beta-hCG and a very low PAPP-A, and an increased NT measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/12,43,44\">",
"     12,43,44",
"    </a>",
"    ]. One study that screened over 8500 women with singleton pregnancies in the first trimester using maternal age, NT, beta-hCG, and PAPP-A detected 10 of 11 fetuses with trisomy 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/12\">",
"     12",
"    </a>",
"    ]. The single false negative case was screen positive for trisomy 21. Thus, screening identified 91 percent of the 11 cases of trisomy 18, with a FPR of 2 percent using a risk cut-off of 1 in 150. In the FASTER trial, 9 of 15 (60 percent) of trisomy 18 cases were identified using a first trimester algorithm, at a 0.1 percent FPR [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In screening for trisomy 18, it is appropriate to keep the FPR very low (less than 0.5 percent) so that only a small number of very high risk women will be offered invasive diagnostic testing to detect a fetal abnormality that is almost always lethal. However, when the FPR is kept very low, the DR will also be reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link&amp;anchor=H4#H4\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\", section on 'Trisomy 18'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Integrated test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The integrated test is highly efficient in identifying cases of trisomy 18. In one study that used a second-trimester risk cut-off of 1 to 100, four serum markers (first trimester PAPP-A with second trimester beta-hCG, AFP, and uE3) in combination with maternal age detected 90 percent of trisomy 18 pregnancies at a FPR of 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/46\">",
"     46",
"    </a>",
"    ]. The risk of a trisomy 18 pregnancy among screen-positive women was 1 in 4. The addition of NT to a trisomy 18 screening algorithm will further improve the performance of the integrated test.",
"   </p>",
"   <p>",
"    The presence of anatomical findings suggestive of trisomy 18 on ultrasound examination is highly dependent upon gestational age, and is most reliable at 19 to 20 weeks of gestation, when DR approaches 100 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER ANEUPLOIDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FASTER trial found that first trimester combined screening detected 78 percent of all non-Down syndrome aneuploidies, with an overall FPR of 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/45\">",
"     45",
"    </a>",
"    ]. These patients were identified as being at high risk for Down syndrome or trisomy 18, or presented with cystic hygroma in the first trimester.",
"   </p>",
"   <p>",
"    In another prospective study, more than 90 percent of trisomy 21, 18, and 13 pregnancies could be detected using a specific algorithm, with an overall FPR of 3.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nuchal translucency alone is a marker of various chromosome abnormalities. About half of the chromosome abnormalities identified by increased nuchal translucency measurements were not trisomy 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the relationship of screen positive results in the first trimester and various chromosome defects other than Down syndrome and trisomy 18, screening for such defects is not warranted. Because of the low prevalence, insufficient data exist to establish rigorous algorithms and to define test performance. Furthermore, many of these defects are either lethal, so that the fetus is often lost early in pregnancy, or mild, so that being subjected to the risk of invasive testing is questionable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ADVERSE PREGNANCY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal maternal Down syndrome screening tests are also predictive of obstetrical complications, but the predictive value of these tests is low. Further investigation is needed to determine whether any type of monitoring and intervention protocol would improve pregnancy outcome and be cost effective when abnormal markers are detected. In the absence of such data, there is no evidence that changes in clinical management are indicated. This topic is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"       \"Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"combined test\" is a first trimester screening test for Down syndrome. It consists of sonographic measurement of fetal nuchal translucency and maternal serum assessment of beta-hCG and pregnancy-associated plasma protein-A, and is commonly performed at",
"      <span class=\"nowrap\">",
"       11",
"       <sup>",
"        0/7ths",
"       </sup>",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       13",
"       <sup>",
"        6/7ths",
"       </sup>",
"      </span>",
"      weeks of gestation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'First trimester combined test'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The combined test detects 85 percent of Down syndrome fetuses at a 5 percent false positive rate (FPR). It is more efficient than the \"quadruple test\" (ie, it has a slightly higher detection rate and a slightly lower FPR), but less efficient than the \"integrated test.\"",
"      <br/>",
"     </li>",
"     <li>",
"      We suggest the combined test for patients who place a higher value on identifying Down syndrome during the first trimester than on the risk of procedure-related pregnancy loss (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Screen positive women should be offered chorionic villus sampling for definitive diagnosis. Women who choose first trimester screening should be offered an ultrasound examination or an alpha fetoprotein (AFP) test in the second trimester to screen for neural tube defects. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The full integrated test (first trimester nuchal translucency, and pregnancy-associated plasma protein-A (PAPP-A) plus second trimester quadruple markers) detects 85 percent of Down syndrome fetuses at a 1 percent FPR. If a 90 percent detection rate is the target, the FPR will be 2 percent. We suggest the full integrated test for patients who place a higher value on minimizing the risk of invasive testing than on",
"      <strong>",
"      </strong>",
"      first trimester identification of an affected pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Results are available in the second trimester and amniocentesis is offered to screen positive patients for definitive diagnosis. Alpha fetoprotein screening for neural tube defects is included. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Integrated tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If nuchal translucency testing is not available, the serum integrated test (first trimester PAPP-A and second trimester AFP, uE3, beta-hCG, and inhibin A) is more efficient than the second trimester quadruple test. At the same detection rate, the serum integrated test has a lower FPR than the quadruple test. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Comparative data from prospective trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stepwise sequential screening, a variant of the integrated test, approximates the performance of the full integrated test and may be a valuable option, as it provides early results for the highest risk patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Step-wise sequential screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combined and integrated tests are also highly effective in identifying fetuses at increased risk of trisomy 18. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Trisomy 18 risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are consistent with the 2007 screening guidelines published by the American College of Obstetricians and Gynecologists, and reaffirmed in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7529/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/1\">",
"      Reddy UM, Mennuti MT. Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop. Obstet Gynecol 2006; 107:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/2\">",
"      Canick JA, Kellner LH. First trimester screening for aneuploidy: serum biochemical markers. Semin Perinatol 1999; 23:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/3\">",
"      Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/4\">",
"      Spencer K, Macri JN, Aitken DA, Connor JM. Free beta-hCG as first-trimester marker for fetal trisomy. Lancet 1992; 339:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/5\">",
"      Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998; 338:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/6\">",
"      Wald NJ, George L, Smith D, et al. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Br J Obstet Gynaecol 1996; 103:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/7\">",
"      Canick JA, Lambert-Messerlian GM, Palomaki GE, et al. Comparison of serum markers in first-trimester down syndrome screening. Obstet Gynecol 2006; 108:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/8\">",
"      Palomaki GE, Lambert-Messerlian GM, Canick JA. A summary analysis of Down syndrome markers in the late first trimester. Adv Clin Chem 2007; 43:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/9\">",
"      Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/10\">",
"      Crossley JA, Aitken DA, Cameron AD, et al. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. BJOG 2002; 109:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/11\">",
"      Krantz DA, Hallahan TW, Orlandi F, et al. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/12\">",
"      Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/13\">",
"      Spencer K, Spencer CE, Power M, et al. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000; 107:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/14\">",
"      Muller F, Benattar C, Audibert F, et al. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn 2003; 23:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/15\">",
"      Bindra R, Heath V, Liao A, et al. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002; 20:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/16\">",
"      Avgidou K, Papageorghiou A, Bindra R, et al. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005; 192:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/17\">",
"      Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/18\">",
"      Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/19\">",
"      Cusick W, Buchanan P, Hallahan TW, et al. Combined first-trimester versus second-trimester serum screening for Down syndrome: a cost analysis. Am J Obstet Gynecol 2003; 188:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/20\">",
"      Gekas J, Durand A, Bujold E, et al. Cost-effectiveness and accuracy of prenatal Down syndrome screening strategies: should the combined test continue to be widely used? Am J Obstet Gynecol 2011; 204:175.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/21\">",
"      Evans MI, Krantz DA, Hallahan TW, Galen RS. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. Am J Obstet Gynecol 2007; 196:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/22\">",
"      Spencer K, Crossley JA, Aitken DA, et al. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002; 39:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/23\">",
"      Szab&oacute; J, Gell&eacute;n J. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 1990; 336:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/24\">",
"      Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992; 304:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/25\">",
"      Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. BJOG 2004; 111:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/26\">",
"      Spencer K, Bindra R, Nix AB, et al. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 2003; 22:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/27\">",
"      Kornman LH, Morssink LP, Beekhuis JR, et al. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 1996; 16:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/28\">",
"      Mol BW, Lijmer JG, van der Meulen J, et al. Effect of study design on the association between nuchal translucency measurement and Down syndrome. Obstet Gynecol 1999; 94:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/29\">",
"      Schielen PC, van Leeuwen-Spruijt M, Belmouden I, et al. Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice. Prenat Diagn 2006; 26:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/30\">",
"      Mennuti MT, Driscoll DA. Screening for Down's syndrome--too many choices? N Engl J Med 2003; 349:1471.",
"     </a>",
"    </li>",
"    <li>",
"     Lambert-Messerlian, GM, Palomaki, GE, Knight, et al. Dimeric inhibin-A as a marker for Down syndrome in the first trimester. Am Coll Med Genet, 2004 Ann Clin Genet Mtg, Mar 4-7, Orlando, FL, Abstr No 63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/32\">",
"      Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/33\">",
"      Rausch DN, Lambert-Messerlian GM, Canick JA. Participation in maternal serum screening following screen positive results in a previous pregnancy. J Med Screen 2000; 7:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/34\">",
"      Palomaki GE, Steinort K, Knight GJ, Haddow JE. Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. Obstet Gynecol 2006; 107:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/35\">",
"      Platt LD, Greene N, Johnson A, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004; 104:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/36\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/37\">",
"      Wright D, Bradbury I, Benn P, et al. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004; 24:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/38\">",
"      ACOG Committee Opinion #296: first-trimester screening for fetal aneuploidy. Obstet Gynecol 2004; 104:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/39\">",
"      Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 2006; 26:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/40\">",
"      Ball RH, Caughey AB, Malone FD, et al. First- and second-trimester evaluation of risk for Down syndrome. Obstet Gynecol 2007; 110:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/41\">",
"      Cuckle HS, Malone FD, Wright D, et al. Contingent screening for Down syndrome--results from the FaSTER trial. Prenat Diagn 2008; 28:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/42\">",
"      Gekas J, Gagn&eacute; G, Bujold E, et al. Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation. BMJ 2009; 338:b138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/43\">",
"      Tul N, Spencer K, Noble P, et al. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999; 19:1035.",
"     </a>",
"    </li>",
"    <li>",
"     Lambert-Messerlian, G, Canick, J, Malone, F, Porter, F, et al. First trimester levels of maternal serum hCG and inhibin A in pregnancies affected by fetal trisomy 18: A FASTER Trial study. Annual Meeting of the American College of Medical Genetics, Orlando, FL, March 4-7, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/45\">",
"      Breathnach FM, Malone FD, Lambert-Messerlian G, et al. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol 2007; 110:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/46\">",
"      Palomaki GE, Neveux LM, Knight GJ, Haddow JE. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn 2003; 23:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/47\">",
"      Kagan KO, Wright D, Valencia C, et al. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod 2008; 23:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7529/abstract/48\">",
"      Kagan KO, Avgidou K, Molina FS, et al. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol 2006; 107:6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 422 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7529=[""].join("\n");
var outline_f7_22_7529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIRST TRIMESTER COMBINED TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Timing of blood sample and ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16165428\">",
"      - Beta-HCG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16165436\">",
"      - PAPP-A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16165460\">",
"      - Nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16165467\">",
"      - Inhibin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTEGRATED TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serum integrated test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Step-wise sequential screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Contingent sequential screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPARATIVE DATA FROM PROSPECTIVE TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      The SURUSS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      The FASTER trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Screen positive first trimester combined test results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Screen positive integrated test results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Screen negative first trimester or integrated test results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Detection of structural anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TRISOMY 18 RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      First trimester combined test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Integrated test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER ANEUPLOIDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ADVERSE PREGNANCY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/422\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/422|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/33/35355\" title=\"table 1\">",
"      Down syndrome screening terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/52/38732\" title=\"table 2\">",
"      Maternal serum marker pattern in selected fetal syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/29/41436\" title=\"table 3\">",
"      Summary of results from FASTER and SURUSS trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/52/29515\" title=\"table 4\">",
"      Odds of Down syndrome after a positive screening test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/57/39835\" title=\"table 5\">",
"      Performance of Down syndrome screening tests by maternal age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=related_link\">",
"      First trimester cystic hygroma and increased nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27257?source=related_link\">",
"      Laboratory issues related to maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=related_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=related_link\">",
"      Second trimester maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_22_7530="Treatment of hypothermia in children";
var content_f7_22_7530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypothermia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7530/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7530/contributors\">",
"     Howard M Corneli, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7530/contributors\">",
"     Robert G Bolte, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7530/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/22/7530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/22/7530/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/22/7530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful resuscitation of the hypothermic child requires rapid attention to supportive care (airway, breathing, circulation), assessment and treatment of injury or medical conditions, and rewarming interventions that vary depending on the degree of hypothermia and the presence or absence of circulation (",
"    <a class=\"graphic graphic_table graphicRef63502 \" href=\"UTD.htm?15/32/15884\">",
"     table 1",
"    </a>",
"    ). In addition, important modifications to advanced cardiac life support are suggested for patients with moderate or severe hypothermia. Although generally harmful, severe hypothermia may also provide cerebral protection against anoxia, allowing cases of remarkable survival after cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This article discusses the treatment of unintentional hypothermia in children. The clinical manifestation of hypothermia in children, neonatal hypothermia, and frostbite are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link\">",
"     \"Clinical manifestations of hypothermia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link&amp;anchor=H6#H6\">",
"     \"Short-term complications of the premature infant\", section on 'Hypothermia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"     \"Frostbite\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia is defined as a core body temperature below 35&ordm;C (95&ordm;F). The stage of hypothermia, defined by core temperature, has a large impact on both recognition and treatment. The most commonly used definitions found in the literature are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild &ndash; Core temperature 32&deg; to 35&ordm;C (90&deg; to 95&ordm;F)",
"     </li>",
"     <li>",
"      Moderate &ndash; Core temperature 28&deg; to 32&ordm;C (82&deg; to 90&ordm;F)",
"     </li>",
"     <li>",
"      Severe &ndash; Core temperature below 28&ordm;C (82&ordm;F)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some experts regard a core temperature &lt;20&ordm;C (68&ordm;F) as profound hypothermia.",
"   </p>",
"   <p>",
"    Of note, these definitions differ from those provided by the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it is important to emphasize that the clinical features of hypothermia may differ from patient to patient so that all cutoffs are relative. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment of mild hypothermia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment of moderate or severe hypothermia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of hypothermia in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In prehospital settings where obtaining a core temperature measurement is challenging, the degree of hypothermia may be estimated from clinical findings as first described by the International Commission for Mountain Emergency Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef88073 \" href=\"UTD.htm?0/5/86\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild (HT I)",
"      </strong>",
"      &ndash; Normal mental status with shivering",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate (HT II)",
"      </strong>",
"      &ndash; Altered mental status without shivering",
"     </li>",
"     <li>",
"      <strong>",
"       Severe (HT III)",
"      </strong>",
"      &ndash; Coma without shivering, vital signs present",
"     </li>",
"     <li>",
"      <strong>",
"       Severe (HT IV)",
"      </strong>",
"      &ndash; No vital signs, resuscitation possible",
"     </li>",
"     <li>",
"      <strong>",
"       Death (HT V)",
"      </strong>",
"      &ndash; Irreversible hypothermia, resuscitation not possible (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Prehospital declaration of death'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for treatment of hypothermia in children are derived from experience in adults and pediatric case reports or case series.",
"   </p>",
"   <p>",
"    Successful resuscitation of the hypothermic child requires rapid attention to supportive care (airway, breathing, circulation), assessment and treatment of injury or other medical conditions, and rewarming interventions that vary based upon core body temperature and the presence or absence of circulation (",
"    <a class=\"graphic graphic_table graphicRef63502 \" href=\"UTD.htm?15/32/15884\">",
"     table 1",
"    </a>",
"    ). Important modifications to standard pediatric advanced life support guidelines are suggested for patients with moderate or severe hypothermia. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Chest compressions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Perfusing bradycardic rhythms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Nonperfusing cardiac rhythms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Core temperature measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accurate measurement of core body temperature in children with hypothermia is essential to proper treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/11\">",
"     11",
"    </a>",
"    ]. Children with suspected hypothermia should have their core temperature taken with a low-reading flexible thermometer probe either rectally or, ideally, at a central site (eg, bladder, esophageal, nasopharyngeal, or central venous site).",
"   </p>",
"   <p>",
"    The clinician should be aware of the following limitations to accurate temperature measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rectal temperature may lag behind core body temperature, sometimes severely. When possible, other central sites are preferred.",
"     </li>",
"     <li>",
"      Rectal and bladder probe readings may rise following peritoneal lavage.",
"     </li>",
"     <li>",
"      Esophageal probe readings may rise due to warm air transmitted through the trachea or following left pleural lavage.",
"     </li>",
"     <li>",
"      Central venous probe readings may rise during rapid infusion of heated fluids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prehospital rescue and triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians may be involved in directing prehospital care and triage of hypothermic patients. Suspicion of hypothermia is vital. Rescuers and medical control clinicians should consider hypothermia, not only in children with obvious environmental exposure, but also in all children who have altered mental status or who require critical care.",
"   </p>",
"   <p>",
"    The measurement of core temperature in the field is difficult. Though subject to artifact, low-reading indirect tympanic thermometers may be useful if they identify the presence of hypothermia. However, these thermometers should not be relied upon to determine definitive warming techniques once the patient arrives in the hospital. The degree of hypothermia may also be estimated from clinical findings in the field (",
"    <a class=\"graphic graphic_table graphicRef88073 \" href=\"UTD.htm?0/5/86\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Core temperature measurement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prehospital declaration of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rescuers should be aware that the clinical appearance of death, including rigidity, is typical of severe hypothermia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of hypothermia in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible or confirmed severe hypothermia is a strong contraindication to the declaration of death in the prehospital setting. &nbsp;Successful resuscitation has occurred in patients with asystole and prolonged avalanche burial (35 minutes or longer) when the airway was patent (not filled with snow or ice) upon extrication [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circumstances that do permit prehospital declaration of death include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rescue is impossible or poses undue risk of serious injury or death to the prehospital providers",
"     </li>",
"     <li>",
"      Injuries are clearly lethal",
"     </li>",
"     <li>",
"      Valid &ldquo;do not resuscitate&rdquo; order is in place",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts also suggest that the prehospital declaration of death may be appropriate in a patient after prolonged avalanche burial (35 minutes or longer) in the combined presence of an obstructed (snow-packed) airway and asystole upon extrication [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prehospital patient care and transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be extracted from the cold environment in a horizontal position, if possible. Prehospital providers should avoid patient exertion and rough handling during rescue of patients with hypothermia because these actions may cause mobilization of cold and acidic blood to the heart and cause cardiac arrhythmias or arrest in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Core afterdrop is the continued cooling of the body after removal from the cold. This is caused both by further conduction of heat away from the core, and circulation of cold blood from the periphery to the core in patients with intact circulation.",
"   </p>",
"   <p>",
"    Many hypothermic patients arrive at the hospital colder than they left the scene. Rescue, transport, and treatment involve several risks for iatrogenic cooling. During transport, rescuers should do all that is possible to prevent further patient heat loss. Key interventions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Removal of wet clothing",
"     </li>",
"     <li>",
"      Gentle insulation of the patient with blankets or other items (eg, sleeping bag)",
"     </li>",
"     <li>",
"      Warming of the transport vehicle",
"     </li>",
"     <li>",
"      Provision of warm IV fluids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children with moderate or severe hypothermia, active external rewarming in transport is avoided in transport. Whether active rewarming promotes core afterdrop in mild hypothermia is controversial. Two small trials in adult volunteers with mild hypothermia indicate that heat applied to the torso only, using forced air heaters, charcoal heaters, or hot water bottles (water temperature 55&deg;C (131&deg;F)) does not prevent core afterdrop but does reduce the temperature decrease by 0.3&deg; to 0.5&deg;C (0.5&deg; to 0.9&ordm;F) when compared with patients who receive only passive rewarming [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. One larger trial in patients with mild hypothermia found that active external rewarming techniques applied to the torso accentuated core afterdrop and concluded that a similar afterdrop in more hypothermic patients could cause harm [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/17\">",
"     17",
"    </a>",
"    ]. The child&rsquo;s increased ability to vasoconstrict the peripheral circulation would argue that afterdrop could be more of a risk in children than adults. We prefer to avoid active external rewarming in transport.",
"   </p>",
"   <p>",
"    If active rewarming is to be performed, rescuers should avoid warming of the extremities and should provide rapid infusion of warmed normal saline with appropriate monitoring of cardiac rhythm. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Active external rewarming'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children with moderate hypothermia warrant transport to a hospital with pediatric intensive care capability [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/9,10,18\">",
"     9,10,18",
"    </a>",
"    ]. Those patients with severe hypothermia should ideally undergo transport to a hospital with active rewarming or cardiopulmonary bypass facilities. Level I designated and pediatric trauma centers usually have such capabilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial hospital care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermic children should be maintained in a horizontal supine position and handled gently with minimization of movement. The clinician should remove wet clothing and insulate the victim from further exposure (eg, dry blankets). The application of external heat, although almost automatic in many centers, should be avoided when circulation is impaired. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Severe hypothermia with absent circulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Administration of heated, humidified oxygen is an acceptable therapy for all hypothermic patients. The amount of rewarming provided by this treatment is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/6\">",
"     6",
"    </a>",
"    ]. The ideal gas temperature, based on the highest delivered temperature that will not cause harm, is 45&deg;C (113&deg;F). However, even at 41&deg;C, inspiration of humidified oxygen prevents further heat loss.",
"   </p>",
"   <p>",
"    Any intravenous (IV) fluid (eg, normal saline), administered in volume should be heated to 40&deg; to 44&deg;C (104&deg; to 111&deg;F) because rapid IV infusion of room temperature (eg, 21&deg;C (70&deg;F)) solutions will cause further cooling and may precipitate ventricular fibrillation or asystole. Setting infusion devices to these temperatures helps avoid delivering fluid that is less than normal body temperature (37&deg;C (98.6&deg;F)) which can worsen core hypothermia.",
"   </p>",
"   <p>",
"    Although heating of IV fluids is vital to prevent further cooling, this method alone cannot transmit enough heat to achieve rewarming [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/19\">",
"     19",
"    </a>",
"    ]. Delivery of warmed IV fluids requires the use of specific technologies, such as trauma-style fluid warmers with short, large-bore insulated, or countercurrent tubing. Standard coil blood warmers will not effectively warm fluid and standard IV tubing will not keep it warm as it passes to the patient. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Vascular access and intravenous fluid therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rewarming techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rewarming is an essential procedure when managing the hypothermic patient. The clinician needs to understand of the classes of rewarming methods available, the proper application of rewarming methods based upon core body temperature and the presence or absence of circulation, and their potential drawbacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Passive rewarming",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive rewarming involves removing cold or wet clothing and applying dry insulation, such as blankets, in a warm environment. Passive rewarming requires the child to generate heat and does not offer specific patient support. Passive methods may help prevent further cooling, but should be accompanied by appropriate active rewarming techniques when treating children with hypothermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Active external rewarming",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active external rewarming techniques apply heat externally to the patient. These include forced air rewarming (",
"    <a class=\"graphic graphic_picture graphicRef51942 \" href=\"UTD.htm?2/52/2884\">",
"     picture 1",
"    </a>",
"    ), radiant heat, and the application of chemical heat packs or plumbed water heating pads. &nbsp;",
"   </p>",
"   <p>",
"    Active external rewarming techniques are simple to perform and are widely available. However, they have the potential to promote afterdrop (further cooling), hypotension (rewarming shock), ventricular fibrillation, or asystole in patients with moderate or severe hypothermia. These adverse effects arise from mobilization of cold and acidic blood into the central circulation, especially if the extremities are warmed early. Thus, when these methods are used, the trunk should be warmed first.",
"   </p>",
"   <p>",
"    Forced air rewarming may lessen the potential for burns of under-perfused skin sometimes seen with the application of direct heat by heating packs or pads [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Small adult series suggest it may also decrease afterdrop [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Active external rewarming may be harmful or ineffective or both in patients with severe hypothermia or absent circulation and should be avoided in such cases unless no other measures are available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Severe hypothermia with absent circulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Active internal rewarming",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques that apply heat internally to the patient are referred to as active internal rewarming.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Noninvasive",
"      </strong>",
"      &ndash; Noninvasive techniques include the provision of heated, humidified oxygen and warmed intravenous normal saline.",
"     </li>",
"     <li>",
"      <strong>",
"       Invasive",
"      </strong>",
"      &ndash; Invasive techniques include heated saline lavage of the left pleural space, bladder, stomach,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneum. Invasive techniques are suggested for patients with severe hypothermia (core temperature &lt;28&ordm;C (82&ordm;F)), especially with some preserved circulation, or those with inadequate response to initial rewarming (",
"      <a class=\"graphic graphic_table graphicRef63502 \" href=\"UTD.htm?15/32/15884\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Severe hypothermia with absent circulation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Extracorporeal",
"      </strong>",
"      &ndash; Extracorporeal techniques include cardiac bypass and extracorporeal membrane oxygenation (ECMO). These are suggested for children with severe hypothermia and absent circulation or in patients for whom other techniques prove ineffective. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Severe hypothermia with absent circulation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF MILD HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with environmental exposure and mild hypothermia (core temperature 32&deg; to 35&deg;C (90&deg; to 95&deg;F)) may respond well to the combination of passive rewarming (removal of wet clothing, drying of skin) and active external rewarming (eg, forced air heating blanket, radiant heat lamp, plumbed water heating pad) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. Administration of warmed intravenous normal saline may also be beneficial. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Vascular access and intravenous fluid therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ongoing monitoring of core temperature and continuous monitoring of cardiac rhythm and circulatory status are essential to ensure that these patients are responding appropriately to rewarming interventions (",
"    <a class=\"graphic graphic_table graphicRef63502 \" href=\"UTD.htm?15/32/15884\">",
"     table 1",
"    </a>",
"    ). Children can show marked core afterdrop (further cooling) even in mild hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants and children with serious underlying medical conditions (eg, sepsis, hypoglycemia, or hyponatremia (",
"    <a class=\"graphic graphic_table graphicRef88088 \" href=\"UTD.htm?10/24/10637\">",
"     table 3",
"    </a>",
"    )) may be more ill-appearing or display symptoms that cannot be attributed to mild hypothermia (eg, lethargy, hypotension). Diagnostic testing and appropriate treatment should be instituted as soon as possible in these circumstances. Rewarming may be incomplete in these patients until the underlying medical etiology is identified and treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link&amp;anchor=H9285874#H9285874\">",
"     \"Clinical manifestations of hypothermia in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF MODERATE OR SEVERE HYPOTHERMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate hypothermia or severe hypothermia require intensive supportive care of the airway, breathing, and circulation in addition to rewarming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Airway and Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypoventilation may be physiologic in moderate or severe hypothermia, careful and gentle respiratory support is safe and should be provided as needed including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Warmed, humidified 100 percent oxygen via nonrebreather mask for all patients",
"     </li>",
"     <li>",
"      Bag-valve-mask ventilation in children with hypoventilation and when preparing for endotracheal intubation",
"     </li>",
"     <li>",
"      Endotracheal intubation in patients with respiratory failure, uncompensated shock, or cardiac arrest",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endotracheal intubation should not be delayed, when indicated, in the hypothermic child. However, it should be performed in a gentle manner with minimal movement of the patient. Cardiac rhythm should be closely monitored during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct laryngoscopy may be difficult in severe hypothermia, because muscular rigidity prevents jaw movement. Oral intubation using advanced airway adjuncts (eg, fiberoptic bronchoscope, video laryngoscopy, bougie) may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39337?source=see_link\">",
"     \"Devices for difficult endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although ventricular fibrillation (VF) has been a theoretical concern in patients with moderate or severe hypothermia who undergo endotracheal intubation, a case series of 428 adults with hypothermia found that none of the 97 patients who were endotracheally intubated and had core temperatures &le;32.2&deg;C (90&deg;F) developed VF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Chest compressions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with severe hypothermia (below 28&deg;C (82&deg;F)), the pulse and respiratory effort may be very slow and difficult to detect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ]. Experts suggest that the clinician start cardiopulmonary resuscitation without delay if there are no signs of life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some instances, the clinician may question whether chest compressions are warranted in severely hypothermic patients with very slow or minimally perfusing cardiac rhythms. Some experts suggest that compressions may be withheld unless a nonperfusing cardiac rhythm (eg, asystole, ventricular fibrillation, pulseless electrical activity) is present. Rapid bedside cardiac ultrasound may assist in differentiating cardiac contractions with a perfusing rhythm from pulseless electrical activity. However, such determinations may be difficult and standard chest compressions should be provided without delay if there is any uncertainty about temperature or a perfusing rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with nonperfusing rhythms should receive chest compressions using standard rates and depths. Chest compressions will be difficult due to muscular rigidity, but the former use of open cardiac massage is now discouraged because the myocardium will also be rigid in such cases, and the closed-chest mechanics of CPR will be lost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link&amp;anchor=H8#H8\">",
"     \"Basic life support in infants and children\", section on 'Chest compressions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vascular access and intravenous fluid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia-induced vasoconstriction may make vascular access difficult, especially in children. However, vascular access is vital because aggressive volume expansion is a cornerstone of treatment for moderate and severe hypothermia. If adequate peripheral intravenous (IV) access (two 22 gauge or larger peripheral IVs) is not rapidly available, then the clinician should place an intraosseous needle or central line via the femoral vein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with moderate or severe hypothermia typically become disproportionately hypovolemic from diuresis and fluid shifts. These patients should initially receive 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of heated (40&deg; to 44&deg;C (104&deg; to 111&deg;F)) intravenous (IV) normal saline using high-capacity warmers and tubing and rapid IV infusion methods. Setting infusion devices to these temperatures helps avoid delivering fluid that is less than normal body temperature (37&deg;C (98.6&deg;F)) which can worsen core hypothermia. Additional IV boluses should be repeated as per standard pediatric shock resuscitation protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial management of shock in children\", section on 'Goal-directed algorithm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of hypothermia in children\", section on 'Other physiologic effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adequacy of volume support can be difficult to assess in the moderately or severely hypothermic patient. Measurements of central venous pressure and central venous oxygen saturation may help guide resuscitation. Femoral central line placement is preferred since catheters placed above the diaphragm may contact the myocardium and precipitate ventricular arrhythmias in hypothermic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H20#H20\">",
"     \"Initial management of shock in children\", section on 'Monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An indwelling bladder catheter should be placed to assess urine output in response to fluid resuscitation. In addition, this monitoring allows for recognition and replacement of excess renal fluid losses that are common in patients with moderate to severe hypothermia. Bladder catheters with built-in temperature probes offer a useful means to monitor core temperature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Glucose homeostatsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is fairly common in hypothermia. If hypoglycemia is known or suspected, intravenous dextrose (0.5",
"    <span class=\"nowrap\">",
"     gm/kg)",
"    </span>",
"    should be administered.",
"   </p>",
"   <p>",
"    Insulin, by contrast, should be withheld when hyperglycemia accompanies hypothermia, as it will not be effective in the cold patient and may later cause hypoglycemia in the rewarmed child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Perfusing bradycardic rhythms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perfusing rhythms associated with hypothermia include sinus bradycardia, first degree atrioventricular block, and atrial fibrillation with slow ventricular response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/26\">",
"     26",
"    </a>",
"    ]. These rhythms are felt to be adequate for maintaining sufficient oxygen delivery in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ]. Bradycardia may be physiologic in severe hypothermia, and cardiac pacing generally is",
"    <strong>",
"     not",
"    </strong>",
"    required unless the bradycardia persists despite rewarming to 32&deg; to 35&deg;C (90&deg; to 95&deg;F). Similarly, medications for bradycardia (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    , epinephrine) may be withheld because perfusing bradycardic rhythms usually convert to sinus rhythm with rewarming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nonperfusing cardiac rhythms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of ventricular fibrillation (VF), ventricular tachycardia without a pulse, pulseless electrical activity (PEA), or asystole is common during treatment of moderate or severe hypothermia. Aggressive active internal rewarming or ideally, extracorporeal rewarming may be the primary treatment in these patients because treatment without rewarming is often ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ]. Case reports with intact neurologic survival have sometimes documented the spontaneous conversion of asystole to VF, and of VF to sinus rhythm with rewarming alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/2,27,28\">",
"     2,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ventricular arrhythmias with hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypothermia and ventricular fibrillation (VF) or ventricular tachycardia (VT) without a pulse may be refractory to conventional therapy until the patient has been rewarmed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ]. These patients may receive initial defibrillation and pharmacologic therapy as indicated by pediatric advanced life support (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 1",
"    </a>",
"    ), but if initial attempts are unsuccessful, CPR and aggressive rewarming must be promptly initiated. We note that refractory VF has been reported in many cases of severe hypothermia, and spontaneous conversion of VF has been observed with rewarming alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Asystole or pulseless electrical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with asystole or pulseless electrical activity (PEA) and severe hypothermia (core temperature &lt;28&deg;C (82&deg;F)) should receive airway support (endotracheal intubation), chest compressions, and extracorporeal rewarming, if available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the efficacy of epinephrine is decreased in patients with severe hypothermia, limited evidence in animal models suggests that return of spontaneous circulation is promoted when epinephrine is used according to pediatric advanced life support guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 1",
"    </a>",
"    ) and in conjunction with aggressive rewarming [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ]. Excessive doses should be avoided.",
"   </p>",
"   <p>",
"    Intravenous dextrose (eg, 0.5",
"    <span class=\"nowrap\">",
"     gm/kg)",
"    </span>",
"    <strong>",
"     should",
"    </strong>",
"    be administered in patients with asystole or PEA for documented or suspected hypoglycemia regardless of core body temperature.",
"   </p>",
"   <p>",
"    Children with asystole or PEA and moderate hypothermia (core temperature 28&deg; to 32&deg;C (82&deg; to 90&deg;F)) should receive medications according to established pediatric advanced life support protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"     5",
"    </a>",
"    ]. Some physicians may choose to increase the spacing between doses until core temperature is &gt;32&deg;C (90&deg;F). In most circumstances, resuscitative efforts should continue until the child's core temperature is 34&deg; to 35&deg;C (93&deg; to 95&deg;F). (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Withholding resuscitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In children with moderate hypothermia (28&deg; to 32&deg;C (82&deg; to 90&deg;F)), clinicians should balance the risks and benefits of each medication while recognizing that intact neurologic survival above approximately 32&deg;C requires rapid restoration of intact circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Duration of resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the neuroprotective effects of hypothermia, complete recovery of patients with hypothermia and cardiac arrest, despite prolonged resuscitation, has been well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. Thus, under usual circumstances, resuscitative efforts should be continued at length (if need be, for hours) until the core temperature is approximately 34&deg; to 35&deg;C (93&deg; to 95&deg;F) or there is return of spontaneous circulation. Resuscitation can be withheld if clearly lethal injuries are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Withholding resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of hypothermia with a core temperature &lt;32&deg;C (90&deg;F) should alter typical resuscitation decisions because intact survival has occurred in such patients despite prolonged resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/2,27,29\">",
"     2,27,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard prognostic rules change in severe hypothermia. For instance, recommendations about the duration of submersion incompatible with survival do not apply in cases of very cold water [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/30\">",
"     30",
"    </a>",
"    ]. Children have survived up to 66 minutes of submersion in very cold water [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/2\">",
"     2",
"    </a>",
"    ]. Review of cases where survival from near-drowning and hypothermic arrest occurred found that the water temperature was usually &lt;5&deg;C (41&deg;F) and almost always &lt;10&deg;C (50&deg;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/31\">",
"     31",
"    </a>",
"    ]. Because water temperature is seldom known with any certainty, resuscitation and rewarming should be provided if any doubt exists.",
"   </p>",
"   <p>",
"    On the other hand, patients who are hypothermic after drowning in water that is obviously not cold (eg, a heated swimming pool) will not be protected from anoxia. In these situations, deviation from the typical duration of resuscitative efforts is not indicated. In addition, the presence of mild hypothermia after prolonged submersion argues against neuroprotection.",
"   </p>",
"   <p>",
"    Similarly, avalanche victims have survived prolonged burial (35 minutes or longer) despite asystole upon extrication when the airway was patent (not packed with snow or ice) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experts have noted that survival is unlikely in patients with a serum potassium &gt;12",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    and this degree of hyperkalemia has been used by some experts as an indication to withhold or cease resuscitation efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/9,32\">",
"     9,32",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Most experts believe that the neuroprotective effect of hypothermia is lost at core temperatures above 32&deg;C (90&deg;F). In patients with a core temperature between 32&deg; and 34&deg;C (90&deg; and 93&deg;F), rewarming is probably indicated, but the clinician must use their best judgment as to the duration of resuscitation. Once the core temperature is above 34&deg; to 35&deg;C (93&deg; to 95&deg;F), resuscitation may be stopped in patients who have not regained spontaneous circulation despite appropriate pediatric advanced life support interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Rewarming",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitions and distinctions among the various rewarming techniques are discussed above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Rewarming techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinicians should determine the method of rewarming based upon the degree of hypothermia and the presence or absence of circulation (",
"    <a class=\"graphic graphic_table graphicRef63502 \" href=\"UTD.htm?15/32/15884\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Moderate hypothermia with intact circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to warmed humidified oxygen and heated intravenous normal saline, we suggest that children with intact circulation and moderate hypothermia (core temperature 28&deg; to 32&deg;C (82&deg; to 90&deg;F)) receive active external rewarming, preferably forced air rewarming (",
"    <a class=\"graphic graphic_picture graphicRef51942 \" href=\"UTD.htm?2/52/2884\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Rewarming shock is a major risk of active external rewarming. Cold, acidemic blood that has pooled in the vasoconstricted extremities of the hypothermic patient returns to the core circulation, causing a drop in temperature and pH. At the same time, external rewarming results in peripheral vasodilation, potentially contributing to hypotension, inadequate coronary perfusion, and ventricular fibrillation. Rewarming shock may be fatal if rewarming is not accompanied by vigorous support of hypovolemic shock and circulatory instability typically seen in children with moderate or severe hypothermia. Thus, children with moderate hypothermia should have appropriate intravenous access and be receiving rapid infusion of warmed normal saline from the initiation of rewarming. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Vascular access and intravenous fluid therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This recommendation for forced air rewarming is based on one small trial and two case series documenting the successful use of forced air rewarming in 28 adults who had core temperatures ranging from 24&deg; to 34&deg;C (75&deg; to 34&deg;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. None of these patients developed core afterdrop or rewarming shock. All patients with intact circulation (N = 22) had complete recovery. Mean core rewarming rate was 1.0&deg; to 2.4&deg;C per hour (1.8&deg; to 4.0&deg;F per hour). Maximum reported rewarming rate was 3.4&deg;C per hour (6.0&deg;F per hour). Successful rewarming using this external method in patients with absent circulation is not well documented.",
"   </p>",
"   <p>",
"    Patients with moderate hypothermia who have a continued drop in core body temperature despite active external rewarming or who develop life-threatening cardiac arrhythmias are candidates for more invasive active internal rewarming methods, such as left pleural lavage or extracorporeal warming methods (eg, cardiac bypass or extracorporeal membrane oxygenation). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Severe hypothermia with intact circulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    To avoid iatrogenic hyperthermia, many clinicians stop external rewarming when the core temperature reaches 35&deg;C (95&deg;F). Continued close temperature monitoring and control are required to avoid re-cooling or an overshoot in temperature. In centers using induced hypothermia after cardiac arrest (currently an investigational intervention in children) the target temperature for rewarming may be modified according to local protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Severe hypothermia with intact circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence exists regarding the best method of rewarming children with this degree of hypothermia. Our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Active internal rewarming",
"      </strong>",
"      &ndash; Because children may be even more prone to afterdrop than adults, and because severe hypothermia may cause severe cardiovascular instability, we prefer that children with severe hypothermia (core temperature &lt;28&ordm;C (82&ordm;F)) but preserved circulation be warmed by active internal methods, if possible rather than forced-air external rewarming alone. These methods include heated saline lavage of the pleural space, bladder, stomach,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneum.",
"      <br/>",
"      <br/>",
"      Left pleural lavage with heated normal saline is our preferred active internal rewarming method [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/33-38\">",
"       33-38",
"      </a>",
"      ]. This procedure is performed by placing two chest tubes in the left pleural cavity that are positioned so that inflow is anterior and drainage is posterior. Fluid heated to 40&deg; to 44&deg;C (104&deg; to 111&deg;F) is instilled through the anterior chest tube and warms the heart directly. Some clinicians, especially those without extracorporeal rewarming methods available to them, have chosen right pleural lavage because it avoids the theoretical risk of the left ventricle being struck by the chest tube during insertion and going into fibrillation. Right pleural lavage may be a less effective method of rewarming.",
"      <br/>",
"      <br/>",
"      Heated normal saline lavage of the stomach, bladder, colon, and peritoneum are generally less effective than pleural lavage, but all have been used successfully in some cases. Gastric lavage risks pulmonary aspiration in these critically ill patients.",
"      <br/>",
"      <br/>",
"      The need to rapidly provide large quantities of heated saline presents a practical problem for all of the lavage techniques. Preplanning may suggest solutions, such as using trauma-suite IV warmers or peritoneal-dialysis heating tubs. In one case, successful resuscitation was achieved with pleural lavage using 75 L of heated tap water [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Forced-air external rewarming",
"      </strong>",
"      &ndash; Heated forced air rewarming alone may be tried in children if active internal rewarming methods are delayed or if large volumes of heated fluid are",
"      <strong>",
"       not",
"      </strong>",
"      readily available [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/10,22-24\">",
"       10,22-24",
"      </a>",
"      ]. If forced-air external rewarming is used, the clinician should be especially vigilant for afterdrop and be prepared to respond to circulatory collapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Severe hypothermia with absent circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with severe hypothermia (core temperature &lt;28&ordm;C (82&deg;F)) and absent circulation undergo rapid rewarming with extracorporeal methods (eg, cardiac bypass or extracorporeal membrane oxygenation [ECMO]), if available.",
"   </p>",
"   <p>",
"    Cardiac bypass or ECMO are the most effective extracorporeal rewarming methods. They can achieve rewarming rates of 9.8&ordm;C per hour (17.6&deg;F per hour). In addition, these methods have been used widely in reported cases of intact neurologic survival from hypothermic cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/39-41\">",
"     39-41",
"    </a>",
"    ] and in children as young as two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/2,18\">",
"     2,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantages of extra-corporeal rewarming include circulatory support, oxygenation with hemodilution, and very rapid rewarming even in cardiac arrest. Because requirements include large-bore arterial and venous cannulation as well as specialized equipment and personnel, a preplanned team approach is ideal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/18\">",
"     18",
"    </a>",
"    ]. Delays, however, have not prevented success. Patient transport for up to three hours and cardiopulmonary resuscitation for up to six hours prior to institution of ECMO or cardiac bypass have still been associated with good outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/42\">",
"     42",
"    </a>",
"    ]. The chief contraindication, severe associated trauma with risk of bleeding due to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    , may be avoided using non-heparinized bypass circuits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When extracorporeal techniques are unavailable or markedly delayed, many other approaches have also succeeded. In these cases, alternative techniques should be attempted. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Active internal rewarming with CPR",
"      </strong>",
"      &ndash; Heated left pleural lavage, as described above, and at times other internal rewarming methods, have been used successfully in cardiac arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/14,44\">",
"       14,44",
"      </a>",
"      ] when extracorporeal rewarming is unavailable or contraindicated [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/34\">",
"       34",
"      </a>",
"      ]. Some clinicians suggest bilateral pleural lavage in these patients, especially in those children who are initially unresponsive to left pleural lavage alone.",
"     </li>",
"     <li>",
"      <strong>",
"       Active external rewarming with CPR",
"      </strong>",
"      &ndash; Although impaired circulation limits the effectiveness and increases the hazards of external rewarming, combined measures including active external rewarming have at times been effective. Forced air rewarming has been used with some success in this setting. Case reports in several children [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/4,38\">",
"       4,38",
"      </a>",
"      ] emphasize that when extracorporeal methods are unavailable, a combination of other methods may be effective.",
"     </li>",
"     <li>",
"      <strong>",
"       Other extracorporeal methods",
"      </strong>",
"      &ndash; Successful core rewarming with intact survival has been described using hemodialysis and hemofiltration systems as well as arteriovenous [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/14\">",
"       14",
"      </a>",
"      ] and venovenous shunts [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/44\">",
"       44",
"      </a>",
"      ]. However, these methods have much slower rewarming rates than ECMO or bypass methods (2&deg; to 3&deg;C per hour (3.6&deg; to 5.4&deg;F per hour) versus 9.8&deg;C per hour (17.6&deg;F per hour)), are not widely available, and may be difficult to perform in infants and young children. When these methods are used, prolonged CPR up to and beyond four hours may be required but may still produce intact recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Endovascular temperature control catheter",
"      </strong>",
"      &ndash; Endovascular temperature control catheters can be placed in a central vein (eg, inferior vena cava) and allow for warmed or cooled fluid, contained in a closed loop system in the tip, to directly heat or cool blood in the central circulation. For example, a case report describes the successful use of this technique in rewarming an adult with severe hypothermia (core temperature of 22.7&deg;C (73.0&deg;F)) and a poorly perfusing cardiac rhythm. Rewarming occurred at a rate of 2.8&deg;C (3.8&deg;F) per hour [",
"      <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/45\">",
"       45",
"      </a>",
"      ]. In this instance, the endovascular temperature control catheter was used instead of cardiac bypass or left pleural lavage and was felt to be less invasive. Further study appears warranted before this method is widely adopted for children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, controlling the rate of warming was emphasized, but experience suggests that the rewarming rate is determined more by the patient's circulation and metabolism than by the clinician. In addition, too rapid rewarming is not an issue if sufficient support is provided for blood volume and circulation. For example, case series and case reports identify over 50 patients with intact survival after profound hypothermia (core temperature &lt;25&deg;C (77&deg;F)) treated with very rapid rewarming using extracorporeal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/39,40,46,47\">",
"     39,40,46,47",
"    </a>",
"    ]. In severe hypothermia, rewarming rates less than 1&deg;C per hour will lead to very long resuscitations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Failure to rewarm",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who fail to rewarm, the clinician should institute more aggressive rewarming techniques. In addition, readily reversible contributing causes, such as hypoglycemia or hyponatremia, should be addressed and the clinician should pursue other potential causes, including sepsis, adrenal insufficiency, and central nervous system injury (",
"    <a class=\"graphic graphic_table graphicRef88088 \" href=\"UTD.htm?10/24/10637\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link&amp;anchor=H9285874#H9285874\">",
"     \"Clinical manifestations of hypothermia in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothermic patients with an obvious source of infection should receive antibiotics. Some experts also suggest that patients who fail to raise their core body temperature at a rate greater than 0.6&deg;C per hour (1&deg;F per hour), despite appropriate rewarming efforts, should be treated empirically with broad spectrum intravenous (IV) antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H9034264#H9034264\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Initial antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to respond to aggressive rewarming measures may also have impaired thermogenesis from noninfectious causes, such as endocrine dysfunction, toxins, and lesions of the central nervous system. In addition to sepsis, adrenal insufficiency may be a potentially treatable condition in children with hypothermia. Thus, empiric treatment with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    may be given based on age (eg, &lt;3 years, 25 mg; 3 to 12 years, 50 mg; 12 years and older, 100 mg) and may be warranted. If possible, the clinician should obtain blood for adrenocorticotropin hormone (ACTH) and serum cortisol prior to steroid treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=see_link\">",
"     \"Treatment of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Frostbite",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cold-induced cutaneous injuries is generally supportive. Patients should receive tetanus prophylaxis, as indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 4",
"    </a>",
"    ). Water bath rewarming (40&deg; to 42&deg;C (104&deg; to 107.6&deg;F)) of affected areas for 15 to 30 minutes following stabilization of the core temperature may limit tissue loss. Treatment of frostbite and other cold injuries is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"     \"Frostbite\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Post-resuscitation care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After successful resuscitation, monitoring of core temperature should continue so that recurrent hypothermia or over-warming is rapidly detected. Key aspects of post-resuscitation care include ongoing support of airway, breathing, and circulation, diagnosis, and treatment of underlying medical conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link&amp;anchor=H9285874#H9285874\">",
"     \"Clinical manifestations of hypothermia in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary edema, coagulopathy, and renal failure are common complications after rewarming that require continued care [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/11\">",
"     11",
"    </a>",
"    ]. These conditions usually resolve within a few days. Neurologic abnormalities may resolve quickly with rewarming or persist for weeks to months even in cases where they eventually resolve. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Prediction of neurologic outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital admission should occur for all children with moderate or severe hypothermia as well as those with mild hypothermia if significant underlying disease (eg, sepsis, child abuse) is present.",
"   </p>",
"   <p>",
"    In cases of moderate to severe hypothermia, we advise early consultation with and arrangement of transport to a center that has pediatric emergency medicine and pediatric critical care expertise, and, ideally, extracorporeal rewarming capability.",
"   </p>",
"   <p>",
"    We strongly advocate the prior establishment of hypothermia management protocols and transfer agreements at both the referring hospital and the receiving regional pediatric center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PREDICTION OF NEUROLOGIC OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because hypothermia is often harmful but may at times allow for remarkable survival after prolonged arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], changes are often required in decisions about neurologic prognosis and withholding or withdrawing life support during the post recovery period.",
"   </p>",
"   <p>",
"    In our experience, the best approach is to rewarm and support the patient and then let the course declare itself. Although concern exists about producing hypothermia survivors who are neurologically devastated, limited evidence suggests that intact neurologic survival in previously healthy patients with severe hypothermia, who experience cardiac arrest, may approach 50 percent and that severely impaired survival may be uncommon. For example, in a series of 46 adults with severe hypothermia (core temperature &lt;28&deg;C (82&deg;F)) and cardiac arrest, 32 patients were selected for rewarming by extracorporeal methods. Fifteen of these patients had long-term survival, and none of the survivors had serious long-term neurologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Full neurologic recovery may not be apparent for months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. Thus, the early prediction of neurologic outcome based on physical examination in hypothermic children may be misleading. In addition, prolonged intensive support (eg, up to five days of ECMO) has been associated with intact recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/27,47\">",
"     27,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognostic scoring systems, such as the Glasgow Coma Scale, have not proved useful for hypothermic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/48\">",
"     48",
"    </a>",
"    ]. Although extreme acidosis, hyperkalemia, and hyperammonemia have been seen in patients who did not survive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], the extremes of these markers in hypothermia survivors have not been clearly defined. For example, case reports have documented intact survival in patients with a serum pH of 6.51 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/51\">",
"     51",
"    </a>",
"    ], and 6.29 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/46\">",
"     46",
"    </a>",
"    ] and a potassium of 11.8",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/52\">",
"     52",
"    </a>",
"    ]. In one case series, the two children with the highest potassium values (6.2 and 7.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    survived, while some children with lower values did not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/22/7530/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=see_link\">",
"       \"Patient information: Hypothermia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothermia is defined as a core body temperature below 35&ordm;C (95&ordm;F). The stage of hypothermia, defined by core temperature, has a large impact on both recognition and treatment. The most commonly used definitions are as follows (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of hypothermia'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Mild",
"      </strong>",
"      &ndash; Core temperature 32&deg; to 35&ordm;C (90&deg; to 95&ordm;F)",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"      </strong>",
"      &ndash; Core temperature 28&deg; to 32&ordm;C (82&deg; to 90&ordm;F)",
"     </li>",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      &ndash; Core temperature below 28&ordm;C (82&ordm;F)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The accurate measurement of core body temperature in children with hypothermia is essential to proper treatment. Children with suspected hypothermia should have their core temperature taken with a low-reading flexible thermometer probe either rectally or ideally, at a central site (eg, bladder, esophageal, nasopharyngeal, or central vein). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Core temperature measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In prehospital settings where obtaining a core temperature measurement is challenging, the degree of hypothermia may be estimated from clinical findings (",
"      <a class=\"graphic graphic_table graphicRef88073 \" href=\"UTD.htm?0/5/86\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of hypothermia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     General treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothermic children should be maintained in a horizontal position and handled gently with minimization of movement. The clinician should remove wet clothing and insulate the victim from further exposure (eg, wrap with dry blankets). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial hospital care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management of hypothermia is directed toward resuscitation, assessment of the extent of injury, and rewarming as guided by core body temperature (",
"      <a class=\"graphic graphic_table graphicRef63502 \" href=\"UTD.htm?15/32/15884\">",
"       table 1",
"      </a>",
"      ). Delivery of heated (41&deg; to 45&ordm;C (105.8&deg; to 113&ordm;F)), humidified oxygen and IV fluids heated to 40&deg; to 44&ordm;C (104&deg; to 111&ordm;F) prevents worsening hypothermia and is reasonable for any patient. The clinician should perform endotracheal intubation in patients with respiratory failure, coma, or shock. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Airway and Breathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with moderate or severe hypothermia typically are hypovolemic and warrant aggressive fluid resuscitation. All intravenous fluids delivered in high volume should be warmed (40&deg; to 44&ordm;C (104&deg; to 111&ordm;F)) to avoid worsening of the child's hypothermia (",
"      <a class=\"graphic graphic_table graphicRef63502 \" href=\"UTD.htm?15/32/15884\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Vascular access and intravenous fluid therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Rewarming",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to warmed humidified oxygen and heated intravenous normal saline, we suggest that children with intact circulation and moderate hypothermia (core temperature 28&deg; to 32&ordm;C (82&deg; to 90&ordm;F)) receive active external rewarming, preferably by forced air rewarming (",
"      <a class=\"graphic graphic_picture graphicRef51942 \" href=\"UTD.htm?2/52/2884\">",
"       picture 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When possible, active external rewarming of the trunk should occur BEFORE the extremities to minimize the chance of hypotension (ie, rewarming shock), ventricular fibrillation, or asystole caused by core afterdrop. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Moderate hypothermia with intact circulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Severe hypothermia with intact circulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Active external rewarming'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with severe hypothermia (core temperature &lt;28&ordm;C (82&ordm;F)) but preserved circulation be warmed by active internal rewarming (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These methods include heated saline lavage of the left pleural space, bladder, stomach,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneum. Heated forced air rewarming may be useful if active internal rewarming methods are delayed or large volumes of heated fluid are unavailable. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Severe hypothermia with intact circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with severe hypothermia (core temperature &lt;28&ordm;C (82&ordm;F)) and absent circulation undergo rapid rewarming with extracorporeal methods (eg, cardiac bypass or extracorporeal membrane oxygenation [ECMO]), if available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Severe hypothermia with absent circulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Pediatric advanced life support",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with moderate or severe hypothermia and nonperfusing cardiac rhythms, extracorporeal or aggressive active internal rewarming is the primary therapy. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Severe hypothermia with absent circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perfusing rhythms associated with hypothermia include sinus bradycardia, first degree atrioventricular block, and atrial fibrillation with slow ventricular response. Cardiac pacing is typically ineffective and is not employed in children with significant hypothermia because perfusing slow cardiac rhythms are felt to be adequate for maintaining sufficient oxygen delivery in these patients. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Perfusing bradycardic rhythms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hypothermia and ventricular fibrillation (VF) or ventricular tachycardia (VT) without a pulse may be refractory to conventional therapy until the patient has been rewarmed. These patients may receive initial defibrillation and pharmacologic therapy as indicated by pediatric advanced life support, but if initial attempts are unsuccessful, basic life support and aggressive rewarming must be promptly initiated. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Ventricular arrhythmias with hypothermia'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Patients with asystole or pulseless electrical activity and severe hypothermia (core temperature &lt;28&ordm;C (82&ordm;F)) should receive airway support (endotracheal intubation), chest compressions, and active internal rewarming (eg, extracorporeal warming). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Asystole or pulseless electrical activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Chest compressions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the neuroprotective effects of hypothermia, complete recovery of patients with hypothermia and cardiac arrest has been well documented despite prolonged resuscitation. Thus, under usual circumstances, resuscitative efforts should be continued at length (if need be, for some hours) until the core temperature is approximately 34&deg; to 35&ordm;C (93&deg; to 95&ordm;F) or there is a return of spontaneous circulation. Resuscitation can be withheld if obviously lethal injuries are present. Some experts also suggest that survival is also unlikely in patients with a serum potassium &gt;12",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Duration of resuscitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Withholding resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/1\">",
"      Danzl DF, Pozos RS, Auerbach PS, et al. Multicenter hypothermia survey. Ann Emerg Med 1987; 16:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/2\">",
"      Bolte RG, Black PG, Bowers RS, et al. The use of extracorporeal rewarming in a child submerged for 66 minutes. JAMA 1988; 260:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/3\">",
"      Hughes A, Riou P, Day C. Full neurological recovery from profound (18.0 degrees C) acute accidental hypothermia: successful resuscitation using active invasive rewarming techniques. Emerg Med J 2007; 24:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/4\">",
"      Fisher JD, Schaefer C, Reeves JJ. Successful resuscitation from cardiopulmonary arrest due to profound hypothermia using noninvasive techniques. Pediatr Emerg Care 2011; 27:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/5\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/6\">",
"      Danzl DF, Pozos RS. Accidental hypothermia. N Engl J Med 1994; 331:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/7\">",
"      Giesbrecht GG. Cold stress, near drowning and accidental hypothermia: a review. Aviat Space Environ Med 2000; 71:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/8\">",
"      Jolly BT, Ghezzi KT. Accidental hypothermia. Emerg Med Clin North Am 1992; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/9\">",
"      Durrer B, Brugger H, Syme D, International Commission for Mountain Emergency Medicine. The medical on-site treatment of hypothermia: ICAR-MEDCOM recommendation. High Alt Med Biol 2003; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/10\">",
"      Brown DJ, Brugger H, Boyd J, Paal P. Accidental hypothermia. N Engl J Med 2012; 367:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/11\">",
"      Corneli HM. Accidental hypothermia. J Pediatr 1992; 120:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/12\">",
"      Boyd J, Brugger H, Shuster M. Prognostic factors in avalanche resuscitation: a systematic review. Resuscitation 2010; 81:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/13\">",
"      Brugger H, Paal P, Boyd J. Prehospital resuscitation of the buried avalanche victim. High Alt Med Biol 2011; 12:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/14\">",
"      Gentilello LM, Cobean RA, Offner PJ, et al. Continuous arteriovenous rewarming: rapid reversal of hypothermia in critically ill patients. J Trauma 1992; 32:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/15\">",
"      Hultzer MV, Xu X, Marrao C, et al. Pre-hospital torso-warming modalities for severe hypothermia: a comparative study using a human model. CJEM 2005; 7:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/16\">",
"      Lundgren JP, Henriksson O, Pretorius T, et al. Field torso-warming modalities: a comparative study using a human model. Prehosp Emerg Care 2009; 13:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/17\">",
"      Harnett RM, O'Brien EM, Sias FR, Pruitt JR. Initial treatment of profound accidental hypothermia. Aviat Space Environ Med 1980; 51:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/18\">",
"      Scaife ER, Connors RC, Morris SE, et al. An established extracorporeal membrane oxygenation protocol promotes survival in extreme hypothermia. J Pediatr Surg 2007; 42:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/19\">",
"      Gill BS, Cox CS Jr. Thermodynamic and logistic considerations for treatment of hypothermia. Mil Med 2008; 173:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/20\">",
"      Feldman KW, Morray JP, Schaller RT. Thermal injury caused by hot pack application in hypothermic children. Am J Emerg Med 1985; 3:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/21\">",
"      Truell KD, Bakerman PR, Teodori MF, Maze A. Third-degree burns due to intraoperative use of a Bair Hugger warming device. Ann Thorac Surg 2000; 69:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/22\">",
"      Koller R, Schnider TW, Neidhart P. Deep accidental hypothermia and cardiac arrest--rewarming with forced air. Acta Anaesthesiol Scand 1997; 41:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/23\">",
"      Steele MT, Nelson MJ, Sessler DI, et al. Forced air speeds rewarming in accidental hypothermia. Ann Emerg Med 1996; 27:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/24\">",
"      Kornberger E, Schwarz B, Lindner KH, Mair P. Forced air surface rewarming in patients with severe accidental hypothermia. Resuscitation 1999; 41:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/25\">",
"      Soar J, Perkins GD, Abbas G, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation 2010; 81:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/26\">",
"      Graham CA, McNaughton GW, Wyatt JP. The electrocardiogram in hypothermia. Wilderness Environ Med 2001; 12:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/27\">",
"      Gilbert M, Busund R, Skagseth A, et al. Resuscitation from accidental hypothermia of 13.7 degrees C with circulatory arrest. Lancet 2000; 355:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/28\">",
"      Hall KN, Syverud SA. Closed thoracic cavity lavage in the treatment of severe hypothermia in human beings. Ann Emerg Med 1990; 19:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/29\">",
"      Lexow K. Severe accidental hypothermia: survival after 6 hours 30 minutes of cardiopulmonary resuscitation. Arctic Med Res 1991; 50 Suppl 6:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/30\">",
"      Quan L, Wentz KR, Gore EJ, Copass MK. Outcome and predictors of outcome in pediatric submersion victims receiving prehospital care in King County, Washington. Pediatrics 1990; 86:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/31\">",
"      Orlowski JP. Drowning, near-drowning, and ice-water drowning. JAMA 1988; 260:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/32\">",
"      Monika BM, Martin D, Balthasar E, et al. The Bernese Hypothermia Algorithm: a consensus paper on in-hospital decision-making and treatment of patients in hypothermic cardiac arrest at an alpine level 1 trauma centre. Injury 2011; 42:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/33\">",
"      Kjaergaard B, Bach P. Warming of patients with accidental hypothermia using warm water pleural lavage. Resuscitation 2006; 68:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/34\">",
"      Plaisier BR. Thoracic lavage in accidental hypothermia with cardiac arrest--report of a case and review of the literature. Resuscitation 2005; 66:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/35\">",
"      Brunette DD, Sterner S, Robinson EP, Ruiz E. Comparison of gastric lavage and thoracic cavity lavage in the treatment of severe hypothermia in dogs. Ann Emerg Med 1987; 16:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/36\">",
"      Otto RJ, Metzler MH. Rewarming from experimental hypothermia: comparison of heated aerosol inhalation, peritoneal lavage, and pleural lavage. Crit Care Med 1988; 16:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/37\">",
"      Winegard C. Successful treatment of severe hypothermia and prolonged cardiac arrest with closed thoracic cavity lavage. J Emerg Med 1997; 15:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/38\">",
"      de Caen A. Management of profound hypothermia in children without the use of extracorporeal life support therapy. Lancet 2002; 360:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/39\">",
"      Walpoth BH, Walpoth-Aslan BN, Mattle HP, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming. N Engl J Med 1997; 337:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/40\">",
"      Silfvast T, Pettil&auml; V. Outcome from severe accidental hypothermia in Southern Finland--a 10-year review. Resuscitation 2003; 59:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/41\">",
"      Coskun KO, Popov AF, Schmitto JD, et al. Extracorporeal circulation for rewarming in drowning and near-drowning pediatric patients. Artif Organs 2010; 34:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/42\">",
"      Althaus U, Aeberhard P, Sch&uuml;pbach P, et al. Management of profound accidental hypothermia with cardiorespiratory arrest. Ann Surg 1982; 195:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/43\">",
"      DelRossi AJ, Cernaianu AC, Vertrees RA, et al. Heparinless extracorporeal bypass for treatment of hypothermia. J Trauma 1990; 30:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/44\">",
"      Br&auml;uer A, Wrigge H, Kersten J, et al. Severe accidental hypothermia: rewarming strategy using a veno-venous bypass system and a convective air warmer. Intensive Care Med 1999; 25:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/45\">",
"      Laniewicz M, Lyn-Kew K, Silbergleit R. Rapid endovascular warming for profound hypothermia. Ann Emerg Med 2008; 51:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/46\">",
"      Wollenek G, Honarwar N, Golej J, Marx M. Cold water submersion and cardiac arrest in treatment of severe hypothermia with cardiopulmonary bypass. Resuscitation 2002; 52:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/47\">",
"      Eich C, Br&auml;uer A, Kettler D. Recovery of a hypothermic drowned child after resuscitation with cardiopulmonary bypass followed by prolonged extracorporeal membrane oxygenation. Resuscitation 2005; 67:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/48\">",
"      Fox JB, Thomas F, Clemmer TP, Grossman M. A retrospective analysis of air-evacuated hypothermia patients. Aviat Space Environ Med 1988; 59:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/49\">",
"      Hauty MG, Esrig BC, Hill JG, Long WB. Prognostic factors in severe accidental hypothermia: experience from the Mt. Hood tragedy. J Trauma 1987; 27:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/50\">",
"      Schaller MD, Fischer AP, Perret CH. Hyperkalemia. A prognostic factor during acute severe hypothermia. JAMA 1990; 264:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/51\">",
"      Mair P, Kornberger E, Furtwaengler W, et al. Prognostic markers in patients with severe accidental hypothermia and cardiocirculatory arrest. Resuscitation 1994; 27:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/22/7530/abstract/52\">",
"      Dobson JA, Burgess JJ. Resuscitation of severe hypothermia by extracorporeal rewarming in a child. J Trauma 1996; 40:483.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6598 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7530=[""].join("\n");
var outline_f7_22_7530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Core temperature measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prehospital rescue and triage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prehospital declaration of death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prehospital patient care and transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial hospital care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rewarming techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Passive rewarming",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Active external rewarming",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Active internal rewarming",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF MILD HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF MODERATE OR SEVERE HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Airway and Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Chest compressions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vascular access and intravenous fluid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Glucose homeostatsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Perfusing bradycardic rhythms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nonperfusing cardiac rhythms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ventricular arrhythmias with hypothermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Asystole or pulseless electrical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Duration of resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Withholding resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Rewarming",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Moderate hypothermia with intact circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Severe hypothermia with intact circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Severe hypothermia with absent circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Failure to rewarm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Post-resuscitation care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PREDICTION OF NEUROLOGIC OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      General treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Rewarming",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6598|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/30/42470\" title=\"algorithm 1\">",
"      Pediatric cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6598|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/52/2884\" title=\"picture 1\">",
"      Forced air rewarming",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6598|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/32/15884\" title=\"table 1\">",
"      Hypothermia treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/5/86\" title=\"table 2\">",
"      ICAR-MEDCOM hypothermia scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/24/10637\" title=\"table 3\">",
"      Conditions causing hypothermia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 4\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=related_link\">",
"      Clinical manifestations of hypothermia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39337?source=related_link\">",
"      Devices for difficult endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=related_link\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/6/109?source=related_link\">",
"      Patient information: Hypothermia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31078?source=related_link\">",
"      Treatment of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_22_7531="Preventing fatal asthma";
var content_f7_22_7531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Steps to prevent fatal and nonfatal asthma exacerbations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Provide verbal and written education about trigger avoidance (eg, aeroallergens, aspirin, NSAIDs)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Educate about early warning signs of deterioration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use objective measures of airflow limitation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Review prednisone based action plan at each visit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arrange frequent visits to assess asthma control",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Optimize controller therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Encourage adherence to medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Encourage smoking cessation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Address illicit drug use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide annual influenza vaccination",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7531=[""].join("\n");
var outline_f7_22_7531=null;
var title_f7_22_7532="Dosing formulation monitor";
var content_f7_22_7532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of immunosuppression dosing, formulations, and monitoring",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Formulations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisone",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Tablets, suspension, parenteral by substitution",
"       </td>",
"       <td>",
"        Blood pressure, glucose, lipids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Tablets, suspension, parenteral",
"       </td>",
"       <td>",
"        CBC, liver tests, pancreas toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycophenolate mofetil",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        Tablets, suspension",
"       </td>",
"       <td>",
"        CBC, abdominal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocphenolate sodium",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        Tablets",
"       </td>",
"       <td>",
"        CBC, abdominal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        Capsules, suspension, parenteral",
"       </td>",
"       <td>",
"        Drug level, creatinine, lipids, K(+), Mg(2+), CNS toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrolimus",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td>",
"        Capsules, suspension, parenteral",
"       </td>",
"       <td>",
"        Drug level, creatinine, glucose, lipids, K(+), Mg(2+), CNS toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sirolimus",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Tablets, suspension",
"       </td>",
"       <td>",
"        CBC, drug level, lipids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Everolimus",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Tablets",
"       </td>",
"       <td>",
"        CBC, drug level, lipids",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7532=[""].join("\n");
var outline_f7_22_7532=null;
var title_f7_22_7533="Low NH4 excretion in CRF";
var content_f7_22_7533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impaired ammonium excretion in chronic renal failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 220px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urinary excretion of ammonium (NH4) in normals (solid line) and patients with chronic renal failure (dashed line) at baseline and after an acid load. The plasma bicarbonate concentration fell from 27 to 22 meq/L in normals and from 22 to 14 meq/L in CRF following the acid load. Ammonium excretion rose markedly in normal subjects but was low at baseline and did not increase in the patients with CRF despite a greater degree of metabolic acidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Welbourne T, Weber M, Bank N. J Clin Invest 1972; 51:1852.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7533=[""].join("\n");
var outline_f7_22_7533=null;
var title_f7_22_7534="Attenuation of beta agonist effect in EIB";
var content_f7_22_7534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Attenuation of salmeterol effect in exercise-induced bronchoconstriction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 268px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percentage fall in FEV1 induced by exercise after the first dose and after four weeks of therapy with placebo or continuous salmeterol (50 &micro;g twice daily). Salmeterol minimized the fall in FEV1 after the first dose compared to placebo but the difference was much smaller and not significant at four weeks.",
"    <div class=\"footnotes\">",
"     FEV1: forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ramage L, Lipworth BJ, Ingram CG, et al, Respir Med 1994; 88:363.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7534=[""].join("\n");
var outline_f7_22_7534=null;
var title_f7_22_7535="Pathway frailty";
var content_f7_22_7535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Hypothesized model of frailty and adverse health outcomes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walston J, Hadley EC, Ferrucci L, et al. Research Agenda for Frailty in Older Adults: Towards a Better Understanding of Physiology and Etiology. J Am Geriatr Soc 2006; 54:991. Copyright &copy; 2006 Wiley-Blackwell.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_22_7535=[""].join("\n");
var outline_f7_22_7535=null;
